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Breast and ovarian cancers are common cancers affecting women. Family history 
of the disease is a major risk factor for both cancers. Even though several 
susceptibility alleles have been identified, genetic predisposition to breast and 
ovarian cancer is still largely unexplained. The majority of the known risk-genes, 
most importantly BRCA1 and BRCA2, play a role in DNA damage repair and 
especially in homologous recombination repair. Important players in 
homologous recombination are the RAD51 paralog genes RAD51C and RAD51D, 
in which rare mutations have been identified in breast and ovarian cancer 
families. RAD54L is another gene involved in homologous recombination and is 
thus a putative candidate susceptibility gene. With the growing number of 
identified risk-genes and the development of efficient next-generation 
sequencing methods, multigene-panels have now largely replaced traditional 
BRCA1 and BRCA2 testing in clinical genetic testing of breast and ovarian cancer 
patients.  
The aim of this study was to identify pathogenic germline mutations in the 
RAD51C, RAD51D, and RAD54L genes in breast and ovarian cancer families and 
to evaluate the association of the identified mutations with breast, ovarian, 
prostate, and colorectal cancer risk in the Finnish population. In addition, 95 
high-risk breast or ovarian cancer patients were investigated with a gene panel 
to study the mutation spectrum of 10 known susceptibility genes and to identify 
new mutations. 
The RAD51C gene was sequenced in 277 and the RAD51D and RAD54L genes 
in 95 familial breast or ovarian cancer patients. Two protein-truncating 
mutations in RAD51C, c.93delG and c.837+1G>A, and one in RAD51D, 
c.576+1G>A, were identified and subsequently genotyped in breast (n ≈ 2000), 
ovarian (n ≈ 500), prostate (n ≈ 1000) and colorectal (n ≈ 1000) cancer patients 
and population controls (n ≈ 2000). Mutations in both genes were enriched in 
ovarian cancer patients. The RAD51C mutations were significantly more frequent 
in familial and unselected ovarian cancer patients and the RAD51D mutation in 
breast-ovarian cancer families than in population controls. The mutation 
frequency in both genes was also significantly increased among patients with a 
personal or family history of ovarian cancer, but did not significantly differ 
between unselected breast cancer patients and population controls. No 
mutations were observed in prostate or colorectal cancer patients. These results 
suggest that germline mutations in RAD51C and RAD51D increase the risk of 
ovarian cancer, but not breast, prostate, or colorectal cancer risk. 
The gene-panel testing identified 12 different pathogenic mutations in 18 of 
the 95 patients (19%), including two patients with two different protein-
truncating mutations. BRCA1 or BRCA2 mutations, including one genomic 
duplication in BRCA1, were identified in 8 patients (8.4%) and mutations in other 
genes in 10 patients (10.5%). The most commonly mutated gene was CHEK2, 
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whereas single mutations were observed in TP53, PTEN, and RAD51C. In addition, 
a novel duplication covering the RAD51C exons 1–7 was identified. Together, the 
BRCA1 duplication and the novel RAD51C duplication accounted for 
approximately 10% of all the observed pathogenic or potentially pathogenic 
mutations. Genotyping of the duplication in breast (n ≈ 2500) and ovarian (n ≈ 
500) cancer patients and population controls (n ≈ 1000) revealed seven carriers 
among the cases, but none among the controls and a significant association with 
ovarian cancer risk. 
This thesis study establishes RAD51C as an ovarian cancer susceptibility gene, 
presents information that strengthens the role of RAD51D mutations in ovarian 
cancer predisposition, and provides valuable new knowledge on the associated 
cancer risks for both genes. The results also highlight the importance of 
comprehensive mutation testing of all the relevant susceptibility genes in the 




Breast cancer is the most common cancer among women worldwide and ovarian 
cancer ranks seventh 1. Despite having a good prognosis, breast cancer is the 
leading cause of female cancer deaths. The prognosis for ovarian cancer is 
substantially worse, it being the deadliest gynecological cancer. One of the 
strongest risk factors for breast and ovarian cancer is a positive family history. 
First-degree relatives of breast and ovarian cancer patients are at an 
approximately two and three-fold increased risk, respectively, compared to the 
general population. Several susceptibility genes have been identified, with most 
of them working in DNA damage response and repair pathways 2. Germline 
mutations in these genes increase the risk of breast or ovarian cancer or both. 
The pathogenic mutations are most commonly protein-truncating, but some 
pathogenic missenses have been recognized while large genomic deletions and 
duplications can also disrupt the genes. Mutations in high and moderate-risk 
genes are rare in the general population but when they do occur they significantly 
increase the cancer risk of the individual. The most important susceptibility 
genes are BRCA1 and BRCA2, which confer a high lifetime risk of both breast and 
ovarian cancer. Mutations in BRCA2 are also associated with an increased risk of 
prostate cancer. In addition, numerous common susceptibility alleles for breast 
and ovarian cancer predisposition have been identified that confer a lower 
increase in cancer risk. They contribute to the cancer burden at the population 
level and modify the cancer risk in women with inherited high or moderate-risk 
mutations. In the isolated Finnish population, the majority of pathogenic 
mutations in the susceptibility genes are accounted for by a few recurrent 
founder mutations. 
Clinical genetic testing of high-risk breast and ovarian cancer patients was 
long restricted to the BRCA1 and BRCA2 genes, but with the development of next-
generation sequencing (NGS) methods and the large number of identified 
susceptibility genes, gene panels are now increasingly utilized 3. This has allowed 
many more women to receive a genetic diagnosis and is valuable for families 
where more than one risk allele is segregating. However, it is still the case that 
often only BRCA1 and BRCA2 may be analyzed for large genomic changes. To 
provide accurate counseling for families with inherited mutations and to 
determine the degree of the associated risk, much more research is warranted 
for the genes included in these panels. 
This thesis study examined the association of RAD51C and RAD51D germline 
mutations with breast, ovarian, prostate, and colorectal cancer risk, as well as the 
role of the RAD54L gene in breast and ovarian cancer predisposition. The 
mutation spectrum of 10 established susceptibility genes among high-risk breast 
and ovarian cancer patients was studied with a gene panel. 
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2 REVIEW OF THE LITERATURE
Cancer is the most common cause of death both in the developed and less 
developed countries 1. Worldwide, 14.1 million new cancer cases and 8.2 million 
cancer deaths were estimated to have occurred in 2012. In Finland, almost 
33 000 new cancer cases were diagnosed in 2015 and more than 12 000 people 
died of cancer 4. The most common causes of cancer death in Finland were lung 
cancer for men and breast cancer for women. 
2.1 BIOLOGY OF CANCER
Cancer is a genetic disease involving uncontrolled cell proliferation. 
Tumorigenesis is a multistep process through which normal cells are 
transformed into malignant cells that form tumors. To become cancerous, cells 
need to acquire several biological capabilities – the hallmarks of cancer: self-
sufficient growth signaling, insensitivity to antigrowth signals, apoptosis 
resistance, limitless replication, sustained angiogenesis, and tissue invasion and 
metastasis, as well as the two emerging hallmarks of reprogramming of energy 
metabolism and escaping immune destruction 5, 6. In addition, two enabling 
characteristics, genomic instability and inflammation, facilitate the acquisition of 
these traits. The proliferation of normal cells is strictly regulated whereas the 
acquired self-sufficiency of growth signals, insensitivity to growth-inhibitory 
signals, evasion of apoptosis, and replicative immortality enable continued 
proliferation of cancer cells 5. The acquired ability to induce and sustain 
angiogenesis – the growth of new blood vessels – provides nutrients and oxygen 
for the tumor. The ability to invade adjacent tissues and to send distant 
metastases enables cancer cells to escape the primary tumor mass to a different 
site in the body with more nutrients and space to grow. The emerging hallmark 
of reprogramming of energy metabolism supports the continuous cell growth 
and proliferation, whereas the second emerging hallmark gives the tumor cells 
the ability to avoid elimination by immune cells 6. Genomic instability, which 
generates genetic alterations, and tumor-promoting inflammation, which may 
supply growth-promoting or other bioactive molecules or release mutagenic 
agents, enable the cells to acquire these capabilities and to become malignant 5, 6. 
The increased mutation rate generated by genomic instability may be a 
consequence of an increased sensitivity to external mutagens, the loss of 
telomeric DNA, or defective genome maintenance, caused by, for example, 
mutated caretaker genes that detect and repair DNA damage. 
Tumors display remarkable heterogeneity; they are composed of a mixture of 
cancer cells and various infiltrating normal cell types, which form the tumor 
microenvironment 6, 7. According to the cancer stem-cell model, only 
subpopulations of tumor cells – the self-renewing cancer stem cells – can initiate 
Review of the literature 
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and sustain tumor growth 7. Recruited normal cells, including endothelial cells, 
pericytes, immune inflammatory cells, and cancer-associated fibroblasts, form 
the tumor microenvironment, which creates much of the cellular heterogeneity 
of tumors 6. The tumor microenvironment plays an important role in 
tumorigenesis and evolves during the tumor progression.  
Tumors arise from a single cell of origin and evolve through clonal 
expansion 8. Tumor progression is driven by sequential acquisition of somatic 
mutations that provide selective growth advantage for the cell in which they 
arise. Mutations in the cells occur relatively randomly. Errors may occur during 
DNA replication, and DNA damage can also be caused by external mutagens, such 
as tobacco smoke and ultraviolet light. If the DNA damage is not repaired, these 
changes will be fixed into mutations that are present in all the cell offspring 9. The 
individual progenitor cell with a growth advantage over its neighbors will be 
positively selected. Additional advantageous mutations in some of the offspring 
cells will give rise to new subpopulations with a further growth advantage. Many 
cells with deleterious mutations are eliminated by natural selection, whereas 
cells carrying alterations that confer the capability to proliferate and survive 
more effectively than others are favored and continue to expand 8.  
Cancer cells harbor large numbers of acquired somatic mutations, such as 
base substitutions, small insertions or deletions, and large rearrangements, as 
well as epigenetic changes 9. Mutations in cancer genomes can be divided into 
causal “driver” mutations and neutral “passenger” mutations 9, 10. Driver 
mutations in cancer genes give growth advantage for the cell and are positively 
selected, whereas passenger mutations do not confer selective growth advantage 
and may occur in any gene. A clear majority of somatic mutations in a cancer 
genome are passengers that are carried to descendent cell clones, but do not 
contribute to tumorigenesis 9-11.  
2.1.1 DNA DAMAGE REPAIR
The DNA damage response network protects cells from detrimental effects of 
DNA damage 12. Checkpoints during the cell cycle ensure that the damage is 
recognized and appropriately repaired before the cell proceeds to proliferate. 
Unrepaired DNA damage can lead to genomic instability – a hallmark of cancer – 
including chromosome breaks, translocations, rearrangements, gene 
amplifications, and deletions. Protein kinases in the DNA damage signaling 
networks and cell cycle checkpoints recognize the damage, delay cell cycle 
progression and recruit and activate repair proteins. If the damage cannot be 
repaired, the DNA damage signaling proteins trigger apoptosis or cellular 
senescence. 
Various distinct repair mechanisms have evolved to fix different types of DNA 
damage 12, 13. Small base lesions caused by oxidation, deamination, and alkylation 
are repaired with base excision repair. Helix-distorting base lesions, such as DNA 
damage caused by ultraviolet light, can be repaired via nucleotide excision repair. 
Base-base mismatches and insertion/deletion loops can occur during DNA 
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replication and recombination, and they are repaired via mismatch repair 
(MMR), which takes place immediately after replication. One the most severe 
forms of DNA damage is DNA double-strand breaks (DSBs). They can arise 
endogenously during replication or from exogenous exposure to radiation or 
other DNA-damaging agents. They are preferentially repaired via error-free 
homologous recombination (HR), whereas non-homologous end-joining (NHEJ) 
is a more error-prone mechanism 12-14. HR takes place in the S and G2 phases of 
the cell cycle when the homologous sister chromatid is available to use as a 
template to ensure accurate repair. In contrast, NHEJ operates throughout the 
cell cycle and can introduce errors as it directly ligates the two ends of broken 
DNA together. Interstrand crosslinks (ICLs) are another highly toxic type of 
lesion which may be caused by environmental mutagens and many 
chemotherapeutic drugs as well as by endogenous products, such as aldehydes 
and nitrous acid 12, 15. Their repair requires interplay between the Fanconi 
anemia (FA) pathway and several other repair mechanisms, including nucleotide 
excision repair, MMR, HR, NHEJ, and translesion synthesis. In addition to ICL 
repair, the FA pathway also stabilizes stalled replication forks. 
2.2 CANCER GENES
Over 200 genes have been recognized to act as driver genes in human cancer, and 
many more are likely to be discovered 10, 16. Alterations in these genes contribute 
to cancer development through the stimulation of cell proliferation or the 
inhibition of cell death or of cell cycle arrest. However, a single mutated gene is 
not enough to cause cancer but several genes need to be altered for an invasive 
cancer to develop 17. 
Cancer genes can be broadly classified into dominantly acting oncogenes and 
recessive tumor suppressor genes 17, 18. Oncogenes encode proteins that control 
cell proliferation or apoptosis, such as transcription factors, growth factors, or 
apoptosis inhibitors 17, 19. In cancer, they are activated via gain-of-function 
mutations, which make the gene constitutively active or active under conditions 
when the gene would normally be inactive. They can be activated by recurrent 
missense mutations affecting specific residues, by chromosomal translocations, 
or by gene amplifications. For example, the BRAF oncogene, which encodes a 
serine/threonine kinase, is somatically mutated in a wide variety of cancers, 
most frequently in melanoma 16, 20. The majority of the mutations are missense 
mutations, affecting a single amino acid in the kinase domain 20. 
In contrast, tumor suppressor genes are disrupted by loss-of-function 
mutations 17, 18. The inactivating mutations are typically protein-truncating 
mutations, while missense mutations affecting essential residues and epigenetic 
silencing can also inactivate tumor suppressor genes. Generally, both alleles of 
the tumor suppressor need to be inactivated for it to contribute to cancer 
development. However, some tumor suppressors may display 
Review of the literature 
14 
haploinsufficiency, i.e. where loss of only one copy of the gene is enough to drive 
tumorigenesis.  
Tumor suppressors can be further categorized into gatekeepers and 
caretakers 17, 18. Gatekeepers are traditional tumor suppressors that directly 
affect cellular proliferation by inhibiting growth or by promoting death 18. A 
classic example is the first characterized tumor suppressor, RB1, which controls 
the cell cycle and is mutated in retinoblastoma 21, 22. Caretakers, sometimes 
categorized separately as stability genes, maintain genomic stability 17, 18. They 
encode proteins that function in DNA repair, such as the breast cancer genes 
BRCA1 and BRCA2 involved in HR. Inactivating mutation in a caretaker gene does 
not directly affect tumor initiation or growth, but leads to an increased mutation 
rate and thus may activate oncogenes or inactivate gatekeepers.  
Another class of genes with an indirect effect on tumorigenesis is 
landscapers 23. They act in neighboring stromal cells and contribute to 
tumorigenesis by creating an abnormal microenvironment for the epithelial cells 
to grow. 
In addition to protein-coding genes, non-coding RNA genes such as 
microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) can contribute to 
tumorigenesis 24-26. MiRNAs are small, approximately 20–22 nucleotide long 
RNAs that are processed from longer precursor RNAs 24, 25. They regulate the 
expression of other genes by binding to messenger RNA (mRNA) and thus 
repress translation. They can function both as oncogenes and tumor suppressors: 
increased expression of oncogenic miRNAs leads to down-regulation of tumor 
suppressors, whereas loss of tumor suppressive miRNAs leads to up-regulation 
of oncogenes. Deregulation of the miRNA gene can result from amplification, 
deletion, deregulation of a transcription factor, or epigenetic changes. The same 
miRNA can function as an oncogene in some tissues and as a tumor suppressor 
in others, depending on its target in the specific tissue. An example of miRNAs 
involved in tumorigenesis are miR-15 and miR-16, which are frequently deleted 
or down-regulated in chronic lymphocytic leukemia, and which target the BCL2 
oncogene involved in the inhibition of apoptosis 27, 28.  
LncRNAs are a less well characterized group of heterogeneous RNAs that are 
longer than 200 nucleotides 26. Their expression is tissue-specific and regulated, 
and they are often differentially expressed in tumors. They contribute to 
tumorigenesis by regulating the expression of other genes via diverse 
mechanisms, for example, by interacting with the epigenetic machinery to silence 
genes or through post-transcriptional events such as splicing or post-
translational modification of proteins. Like miRNAs, lncRNAs can function as 
oncogenes or tumor suppressors. Many lncRNAs regulate the expression of the 




2.2.1 HEREDITARY PREDISPOSITION TO CANCER
Pathogenic germline mutations in oncogenes and tumor suppressor genes cause 
hereditary predisposition to cancer 17, 18, 29. The majority of cancer predisposing 
mutations are in tumor suppressor genes, and mutations in caretakers are 
especially common. For instance, BRCA1 and BRCA2 caretaker gene mutations 
predispose to breast and ovarian cancer 30, 31. Only a few oncogenes with 
inherited germline mutations have been recognized 29. Rare examples are 
germline mutations in the RET oncogene, predisposing to multiple endocrine 
neoplasia type 2A, and MET mutations predisposing to papillary renal 
carcinoma 32-34.  
Even though many cancer genes, especially caretakers, function in almost 
every cell of the body, inherited mutations in them usually predispose to specific 
tumor types in certain tissues 17. For example, defects in MMR genes 
predominantly predispose to colorectal cancer and mutations in BRCA1 and 
BRCA2 to breast and ovarian cancer, yet the normal protein products of these 
genes have ubiquitous roles in DNA repair 17, 30, 31, 35-38. 
The inheritance pattern in cancer susceptibility is mainly autosomal 
dominant with varying penetrance, even though on the cellular level, tumor 
suppressor genes act in a recessive manner 29, 39. According to Knudson’s “two-
hit” model, two independent mutational events are required for tumor 
development 22, 40. In the hereditary form of cancer, the first mutation is inherited 
in the germline and the second allele of the tumor suppressor is inactivated 
somatically. For non-hereditary sporadic cases, both mutations are somatic. 
Individuals with a germline mutation usually develop cancer at a younger age, 
and they often develop multiple tumors as only one additional somatic mutation 
is required to initiate tumorigenesis. However, for most tumors to develop into 
malignant cancers, additional mutations in other genes are required. Most 
cancers have inactivated RB1 or TP53, or other genes in the same pathways, 
which control cell-cycle and apoptosis 17, 22. Moreover, high-penetrance 
mutations in tumor suppressor genes are rare in the population and much of the 
inherited susceptibility to cancer is thought to be polygenic, resulting from 
multiplicative effects of several co-inherited lower-penetrance variants 39. 
2.3 BREAST CANCER
Breast cancer is the most common cancer and the leading cause of cancer deaths 
among women worldwide, accounting for 25% of all female cancer cases and 
15% of female cancer deaths 1. In developed countries, however, lung cancer has 
become the leading cause of female cancer mortality. Worldwide, 1.7 million 
breast cancer cases and half a million deaths were estimated as occurring in 
2012. In Finland, 5161 female breast cancer cases were diagnosed in 2015, 
comprising 32% of all female cancer cases 4. The lifetime risk of breast cancer for 
a Finnish woman is over 10%. Breast cancer is the leading cause of cancer deaths 
for women in Finland also, with 841 deaths observed in 2015, accounting for 
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15% of all female cancer mortality. Male breast cancer, however, is a rare disease, 
though the incidence has been increasing. On average, approximately 20 male 
breast cancer cases are diagnosed in Finland annually. 
Despite the large numbers of breast cancer deaths, the prognosis is generally 
good; Finland has one of the top survival rates among European countries, with 
an over 90% 5-year relative survival ratio 4, 41. Over the past decades, the breast 
cancer incidence rate has been increasing worldwide, whereas the mortality rate 
has been decreasing in developed countries 1, 4, 42. In more recent decades, 
however, declining or stable incidence rates have been seen in many Western 
countries, although not in Finland 1, 4. These changes in the incidence rates are 
mainly due to changes in reproductive factors, use of postmenopausal hormone 
replacement therapy, and increased mammographic screening 1, 42. Decreased 
use of hormone therapy as well as plateau reached in screening participation 
probably account for the recent decline in incidence. Early detection due to the 
increased screening has reduced mortality along with improved treatment 1, 42, 43. 
2.3.1 BREAST CANCER CLASSIFICATION AND SUBTYPES
The female breast consists of lobules – the functional milk-producing units – and 
milk ducts, as well as surrounding fat and connective tissue 44. Breast carcinomas 
originate from the epithelial cells lining the terminal duct lobular unit. Invasive 
carcinomas have spread outside the basement membrane of the ducts and 
lobules into the normal tissue, whereas in situ tumors remain within the 
basement membrane.  
Breast cancer is a very heterogeneous disease with over 20 different 
histological types recognized by the WHO 45. Most breast cancers are invasive 
ductal carcinomas of no special type; these account for up to 75% of all invasive 
breast carcinomas. Special types of breast cancer include classical lobular 
carcinoma, which is the second most common subtype, comprising up to 15% of 
all invasive carcinomas, and several rare subtypes, such as medullary, mucinous, 
and tubular carcinomas 45, 46. The different subtypes vary in their morphology 
and clinical outcome.  
Breast cancers can be classified according to grade, stage, and 
immunohistochemical (IHC) score, which are classical predictors of prognosis 
that guide the selection of treatment options 45, 47, 48. The histological grading is 
based on the degree of differentiation of the tumor tissue and is defined by three 
morphological features: tubule formation, nuclear pleomorphism, and mitotic 
count 47, 49. It ranges from more differentiated grade I tumors with a good 
prognosis to poorly differentiated grade III tumors with a worse prognosis. The 
TNM staging system is based on the primary tumor size (T), the status of the 
regional lymph nodes (N), and the presence of distant metastases at diagnosis 
(M) 50. IHC staining of estrogen receptor (ER), progesterone receptor (PR), Ki67 
proliferation marker, and HER2 (also known as ERBB2) expression can be used 
to broadly classify breast cancers 48.  
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Gene-expression profiling allows more detailed classification of breast 
cancers into four intrinsic molecular subtypes: luminal A and B, basal-like or 
triple-negative, and HER2-positive (HER2+) cancers (Table 1) 51-53. Ductal and 
lobular carcinomas can fall into any of these molecular subtypes, whereas the 
rare special histological types typically represent only one molecular subtype 46. 
For instance, tubular and mucinous carcinomas with a good prognosis are 
usually of the luminal A subtype whereas medullary cancers are triple-negative.  
Luminal cancer cells resemble the inner luminal, while basal-like cancer cells 
resemble the outer basal epithelial cells of the milk ducts, and the two can be 
distinguished by the IHC staining of cytokeratins 8/18 and 5/6, respectively 51. 
Luminal cancers have a better prognosis than basal-like or HER2+ cancers (Table 
1) 45, 52-55. The most common subtype is Luminal A, which also has the best 
prognosis. Luminal B tumors are larger and more poorly differentiated than 
luminal A tumors. Somatic TP53 mutations, which are associated with poor 
prognosis, are found only in a minority of luminal A tumors, whereas they are 
more common in luminal B tumors and found in a majority of basal-like and 
HER2+ tumors. As luminal cancers usually express ER, they can be treated with 
endocrine therapy.  Treatment of basal-like carcinomas is mainly limited to 
chemotherapy as they are typically triple-negative, i.e. negative for ER, PR, and 
HER2. HER2+ cancers overexpress HER2, usually through DNA amplification of 
the HER2 locus, and thus can be treated with anti-HER2 agents. 
 
Table 1. Characteristics of the intrinsic molecular subtypes of breast cancer
Subtype Typical IHC pattern TP53 mutations Prognosis




Luminal B ER and/or PR positive
HER2 positive or negative
high Ki67
Common Intermediate
Basal-like ER, PR and HER2 negative Majority Poor
HER2+ ER and PR negative
HER2 positive





Even more refined clustering into ten integrative clusters (IntClust 1–10) can be 
achieved by combining gene-expression with copy-number analysis 55, 56. Tumors 
in different clusters have distinct genomic alterations and clinical outcomes and 
the intrinsic molecular subtypes are split between many clusters (Table 2). 
 
Review of the literature 
18 








1 Chr17/Chr20 ER pos Luminal B Intermediate
2 Chr11 ER pos Luminal A and B Poor
3 Very few ER pos Luminal A Good
4 Very few ER pos or neg Luminal A (mixed) Good
5 Chr17
(HER2 locus)
ER pos or neg,
HER2 pos
Luminal B and HER2+ Very poor (without
anti-HER2 therapy)
6 Chr8 ER pos Luminal B Intermediate
7 Chr16 ER pos Luminal A Good
8 Chr1/Chr16 ER pos Luminal A Good
9 Chr8/Chr20 ER pos Luminal B (mixed) Intermediate
10 Chr5/Chr8/
Chr10/Chr12
TNBC Basal-like Poor 5-year, good
long-term
Chr = chromosome, pos = positive, neg = negative 
2.3.2 BREAST CANCER RISK FACTORS
As is typical for most cancers, breast cancer incidence increases with age, making 
age one of its strongest risk factors 22, 57. Other well-established risk factors 
include reproductive and hormonal factors such as early menarche, late 
menopause, low parity, and older age at first birth 57. Breastfeeding has been 
shown to decrease the risk of breast cancer 58. Long-term postmenopausal 
hormone therapy with combined estrogen and progestogen increases breast 
cancer risk, whereas the contribution of oral contraceptives is unclear, with a 
modest increase in risk at most 59, 60. Some lifestyle-related factors, such as excess 
body weight, alcohol consumption, and physical inactivity, increase the risk 57, 61-
63. Recent studies indicate that smoking is also associated with breast cancer risk 
and mortality 64, 65.  
Even though environmental and lifestyle factors account for majority of the 
breast cancer cases, genetic predisposition is also an important risk factor 57. 
Family history of the disease increases breast cancer risk significantly; however, 
most breast cancer patients do not have family history and most female relatives 
of breast cancer patients do not develop the disease 66, 67. First-degree relatives 
of breast cancer patients are estimated to have an approximately two-fold risk 
and the risk increases with increasing number of affected relatives as well as with 
younger affected relatives. The genes as well as the environmental and lifestyle 
factors shared between family members contribute to the familial aggregation of 
the disease 57. The heritability of breast cancer – the proportion of the variation 
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in risk in a population attributable to genetic differences between individuals – 
is estimated to be 31%, whereas common environmental factors are estimated 
to explain 16% of the variability 68. The heritability estimate includes variation 
in susceptibility genes that directly affect breast cancer risk as well as genetic 
variation that contributes to breast cancer risk factors such as obesity. High-risk 
mutations, such as in BRCA1 and BRCA2, are rare in the general population, but 
they increase the risk of individuals remarkably 69, 70. On the other hand, lower-
risk variants are more common in the population but their contribution to breast 
cancer predisposition at the level of the individual is modest.  
2.4 OVARIAN CANCER
Ovarian cancer is the 7th most common cancer and the 8th most common cause of 
cancer deaths among women worldwide, with 238 700 cases and 151 900 deaths 
estimated to have occurred in 2012 alone 1. In Finland, 436 women were 
diagnosed with ovarian cancer in 2015, comprising 2.7% of all female cancer 
cases and making ovarian cancer the 11th most common cancer among the 
women 4. In female cancer mortality, however, ovarian cancer ranks 5th in 
Finland, with 349 deaths observed in 2015. The lifetime risk of ovarian cancer 
for a Finnish woman is a little over 1%. The prognosis for ovarian cancer is 
markedly worse than for breast cancer, and it is the most lethal gynecologic 
cancer; the 5-year relative survival ratio in Finland is 43% 4. A decline in the 
ovarian cancer incidence rate has been observed in the past decades, but very 
little improvement is seen in the survival rates 41, 71. These rates likely reflect the 
use of oral contraceptives, which decreases the risk of ovarian cancer, but also 
the lack of improvements in early detection. 
2.4.1 OVARIAN CANCER CLASSIFICATION AND SUBTYPES
Ovarian cancer is an even more heterogeneous disease than breast cancer. 
Approximately 90% of ovarian cancers are carcinomas originating from 
epithelial cells, and a small minority are germ cell tumors and sex cord-stromal 
tumors 72.  
Ovarian carcinomas can be divided into two distinct categories: type I and 
type II tumors (Table 3) 73, 74. Type I tumors are less frequent and are often 
diagnosed at an early stage when they are confined to the ovaries. Type II tumors 
account for the majority of ovarian cancers and they are usually diagnosed at an 
advanced stage as they are very aggressive and evolve rapidly. While type I 
tumors have relatively good prognosis, type II tumors have very poor prognosis, 
accounting for 90% of ovarian cancer deaths.  
Several different histologic types have been recognized and according to the 
2014 WHO classification, invasive ovarian carcinomas can be classified into low 
and high-grade serous, mucinous, seromucinous, endometrioid, clear cell, and 
undifferentiated carcinomas, and malignant Brenner tumors 75. Low-grade 
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serous (LGSC), endometrioid, clear cell, seromucinous, and mucinous carcinomas 
as well as Brenner tumors are included in type I tumors (Table 3) 74. Even though 
type I tumors represent distinct histologic subtypes, they all progress in a similar 
stepwise manner from benign cystic neoplasms to intermediate borderline 
tumors and finally to invasive cancers. They are relatively stable genetically and 
do not usually harbor somatic TP53 mutations. Specific mutational patterns are 
found in different histotypes, for instance, KRAS and BRAF mutations are often 
observed in LGSCs and mucinous tumors, while ARID1A, PTEN, and PIK3CA 
mutations are typical for endometrioid and clear cell tumors. 
 
Table 3. Type I and type II ovarian carcinomas















Mucinous carcinoma Tuboperitoneal junction
Brenner tumors Tuboperitoneal junction
Type II









carcinoma Possibly fallopian tube Unknown
 
 
The majority of type II tumors – and of all ovarian cancers – are high-grade serous 
carcinomas (HGSCs) 74. Serous ovarian carcinomas were formerly graded on a 
continuous scale from grade 1 to grade 3, but are now divided into low and high-
grade carcinomas corresponding to type I and type II tumors, respectively 75. The 
former grade 2 serous tumors with wild type TP53 are now classified as low-
grade, and the ones with aberrant TP53 immunostaining are classified as high-
grade 75, 76. Based on gene-expression, HGSCs can be further clustered into four 
molecular subtypes – immunoreactive, differentiated, proliferative, and 
mesenchymal – with different clinical outcomes 74, 77. Other less common and 
less-well characterized type II tumors include undifferentiated carcinomas, and 
carcinosarcomas that are composed of carcinoma and sarcoma (Table 3) 74. Type 
II tumors are morphologically more homogeneous than type I tumors and have a 
different mutational spectrum. High frequency of somatic TP53 mutations, 
chromosomal instability, which leads to widespread copy-number alterations,  
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and defective homologous recombination repair are typical features of HGSCs. 
BRCA1 and BRCA2 mutations, both germline and somatic, are often observed in 
HGSCs. 
The current view is that ovarian carcinomas largely originate from tissues 
outside of the ovaries, with serous tumors mainly arising from the distal fallopian 
tubes, endometrioid, clear cell, and seromucinous tumors from endometriosis, 
and mucinous and Brenner tumors possibly from transitional epithelium at the 
tuboperitoneal junction (a site adjacent to the fallopian tubes and ovaries) (Table 
3) 74. Even though all HGSCs may not originate from the fallopian tubes, serous 
tubal intraepithelial carcinoma (STIC) has been identified as a precursor lesion 
in a large portion of them, especially in patients with BRCA1/2 mutations 78, 79. 
The tumor-suppressive microenvironment of the fallopian tubes and the more 
hospitable ovarian microenvironment may explain why carcinomas develop 
predominantly in the ovaries rather than in the fallopian tubes 80. 
Regardless of their cellular origin, all ovarian, fallopian tube, and peritoneal 
cancers are staged together under the FIGO classification system – from Stage I 
tumors confined to ovaries or fallopian tubes to the most advanced Stage IV 
tumors with distant metastases 72. Stage and histologic type are major factors 
affecting the prognosis of patients and guiding the treatment options. 
2.4.2 OVARIAN CANCER RISK FACTORS AND PREVENTION
STRATEGIES
Similar to breast cancer, the major factors affecting ovarian cancer risk are 
reproductive and hormonal factors. Parity is a major protective factor and 
breastfeeding also decreases the risk 81. Another strong protective factor is the 
use of oral contraceptives, whereas hormone-replacement therapy may increase 
the risk slightly although the association is less clear 59, 60, 81-83. Studies on ovarian 
cancer risk and age at menarche and menopause have been somewhat 
inconsistent, but the results of a meta-analysis and a large cohort study indicated 
an inverse association for age at menarche and a positive association for age at 
menopause 81, 84, 85. Polycystic ovarian syndrome is also a known risk factor 81. 
Environmental or lifestyle factors that may increase the risk of ovarian cancer 
include obesity 86-88 and smoking 89, 90 but their effect is rather modest. 
There is substantial variation in risk factors between different subtypes, and 
most of the established risk factors have weaker associations with the most 
common serous subtype 91. In a recent large prospective study, parity had the 
strongest association with endometrioid and clear cell carcinomas, while age at 
menopause was significantly associated only with these subtypes 91. However, 
most of the hormonal and reproductive risk factors were also associated with an 
overall ovarian cancer risk. Consistent with the endometriotic origin of clear cell 
and endometrioid ovarian carcinomas, endometriosis is a risk factor for these 
subtypes and also for LGSC 91, 92. Of life-style factors, smoking increases the risk 
of mucinous ovarian cancer but has very little effect on the overall ovarian cancer 
Review of the literature 
22 
incidence 89-91, and obesity increases the risk of the rarer subtypes but not the 
common HGSC 87.  
Family history of the disease is a significant risk factor for ovarian cancer 93, 94. 
First-degree relatives of ovarian cancer patients are estimated to have 
approximately three times greater risk of ovarian cancer than women in the 
general population, and the risk is even higher for relatives of younger patients. 
The heritability of ovarian cancer is estimated to be 39% 68. BRCA1 and BRCA2 
mutations are estimated to account for approximately 25% of the familial 
relative risk of ovarian cancer among first-degree relatives 94. While first-degree 
relatives of ovarian cancer patients who are BRCA1/2-negative also have a 
significantly elevated risk, relatives of carriers of BRCA1/2 mutations have a 
significantly higher risk. 
As ovarian cancers are often diagnosed at an advanced stage, improved 
methods for prevention and early detection are warranted. The effect of ovarian 
cancer screening with transvaginal ultrasound and serum CA-125 testing on 
ovarian cancer mortality has been studied in clinical trials, but significant 
survival benefit has not been observed 95, 96. Thus, primary prevention may be a 
more promising strategy. The risk of ovarian cancer can be reduced with oral 
contraceptives and bilateral salpingectomy, whereas tubal ligation only reduces 
the risk of endometrioid and clear cell subtypes 74, 80, 91. As the removal of 
fallopian tubes has no known adverse side-effects, an opportunistic 
salpingectomy can be performed at the time of other pelvic surgery or instead of 
tubal ligation, and prophylactic salpingectomy can be offered to women at 
increased risk of ovarian cancer 74, 80. Bilateral salpingo-oophorectomy is well-
established as the most effective preventive measure traditionally offered for 
high-risk women with BRCA1/2 mutations, but it is associated with adverse side-
effects such as increased risk of cardiovascular disease 97. As BRCA1/2 mutation 
carriers typically develop HGSCs originating from tubal cells, salpingectomy 
possibly coupled with delayed oophorectomy might be sufficient and the adverse 
effects associated with premature surgical menopause could be avoided 74, 80, 97. 
However, more research is required before the efficacy and safety of 
salpingectomy can be determined. 
2.5 BREAST AND OVARIAN CANCER SUSCEPTIBILITY
GENES
Almost all known breast and ovarian cancer susceptibility genes encode tumor 
suppressors that function in the DNA damage response and repair pathways 2. 
The major affected pathway in predisposition to breast and ovarian cancer is HR, 
but the FA and MMR pathways are also indicated.  
The susceptibility genes and risk-variants can be divided into three groups: 
high-penetrance genes that confer a greater than 4 or 5-fold relative risk, 
moderate-penetrance genes conferring an approximately 2 to 5-fold risk, and 
low-penetrance genes or variants generally conferring a lower than 1.5-fold 
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risk 3, 69. Pathogenic mainly protein-truncating mutations in the high and 
moderate-penetrance genes are rare and only these are considered to have 
clinical significance. The low-penetrance variants are common with typical 
minor-allele frequencies (MAF) greater than 1% and they usually reside in non-
coding regions of the genome. They contribute to cancer burden at the 
population level, but single variants do not make a significant difference in the 
cancer risk of an individual. Multiple low-penetrance variants, however, can be 
combined to stratify women into different risk categories 98.  
Despite the vast amount of research and growing number of identified 
susceptibility genes and loci, the majority of the genetic predisposition to breast 
and ovarian cancer remains unexplained 69, 98-100. Thus, many more genes and 
susceptibility loci are yet to be discovered. 
2.5.1 HIGH-PENETRANCE GENES
2.5.1.1 BRCA1 and BRCA2
The most important susceptibility genes for both breast and ovarian cancer are 
BRCA1 and BRCA2, which were discovered through family based linkage-
studies 2. The first breast cancer gene identified was BRCA1 in 1994 shortly 
followed by the identification of BRCA2 in 1995 30, 31. Women with BRCA1 or 
BRCA2 mutations have a high lifetime risk of breast and ovarian cancer (Table 4) 
70, 101, 102. The prevalence of BRCA1 and BRCA2 mutations among breast and 
ovarian cancer families is approximately 25%, but the prevalence varies greatly 
according to the type of family history as well as between different 
populations 103. In Finland, BRCA1/2 mutations have been observed in 21% of 
breast and 26% of ovarian cancer families, and in 1.8% and 5.6% of unselected 
breast and ovarian cancer patients, respectively 104-107.  
The mutation carriers have an approximately 10 to 30-fold increased risk of 
breast cancer compared to the general population, but the relative risk decreases 
with age, especially for BRCA1 carriers 101. The ovarian cancer risk for BRCA1 
carriers is substantially higher than for BRCA2 carriers. In a recent large 
prospective study, women with BRCA1 mutations were estimated to have a 72% 
and 44% risk of developing breast and ovarian cancers, respectively, by age 80 70. 
For women with BRCA2 mutations the risk estimates were 69% for breast cancer 
and 17% for ovarian cancer. As a comparison, the estimated cumulative risks of 
breast or ovarian cancer by age 80 for a Finnish woman in the general population 
are 10.8% and 1.12%, respectively 4. The breast cancer risk for both BRCA1 and 
BRCA2 carriers increases with an increased number of affected family 
members 70. For women without a family history, the estimated risks are likely 
overestimated, as the study cohort was ascertained mainly through cancer 
genetic clinics and was enriched for women with a strong family history. For men 
with BRCA1 or BRCA2 mutations, the estimated risk of developing breast cancer 
by age 70 is 1.2% and 6.8%, respectively 108.  
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Table 4. Estimated cancer risks associated with established breast and ovarian cancer
susceptibility genes. For high-penetrance genes, the risks are estimated primarily as absolute
risks; for moderate-penetrance genes, as both absolute and relative risks.
Gene Breast cancer risk Ovarian cancer risk References
High-penetrance genes
BRCA1 72% by age 80 44% by age 80 70
BRCA2 69% by age 80 17% by age 80 70
TP53 85% by age 60 - 109
PTEN 67–85% lifetime risk - 110
STK11 31–54% by age 60 - 111
CDH1 42% by age 80 - 112
NF1 RR ≈ 6.5–11 for women aged<40 years; 26% by age 80 - 113, 114
MLH1, MSH2,
MSH6, and PMS2 - 6–14% lifetime risk 115
Moderate-penetrance genes
ATM RR ≈ 3; 27% by age 80 - 3, 116
CHEK2 RR ≈ 2–3; 20% by age 80 - 117, 118
PALB2 RR ≈ 5; 35% by age 70 - 3, 119
BRIP1 - RR ≈ 3.4–11; 6% by age 80 120
RAD51C - RR ≈ 5.9; >9% by age 80 121
RAD51D - RR ≈ 6.3; 10% by age 80 122
RR = relative risk 
 
The majority of the breast tumors in BRCA1 and BRCA2 mutation carriers are 
ductal carcinomas; however, medullary tumors are more common among BRCA1 
carriers than among BRCA2 carriers, whereas lobular tumors are more common 
among BRCA2 carriers 123. The BRCA1 and BRCA2 tumors are often high grade, 
but BRCA1 tumors are more commonly grade 3 than BRCA2 tumors. BRCA1 
breast tumors are usually ER-negative or triple-negative, whereas BRCA2 tumors 
are typically hormone receptor positive 123-125. The majority of the ovarian 
tumors in BRCA1 and BRCA2 mutation carriers are HGSCs 74, 123. Despite the 
tumor features associated with poor prognosis, the evidence for worse survival 
among breast cancer patients with germline BRCA1/2 mutations compared to 
non-carriers is inconclusive 126. For ovarian cancer patients with BRCA1/2 
mutations, the short-term survival is better than for non-carriers, but the 
advantage decreases over time and for BRCA1 carriers, the long-term survival is 
worse than for non-carriers 127.  
The main function of BRCA1 and BRCA2 is to promote repair of DSBs via HR 2. 
Additional roles for BRCA1 and BRCA2 in genome maintenance include DNA-
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damage checkpoint signaling as well as the protection of DNA replication forks 
and ICL repair via the FA pathway 2, 15. 
BRCA1/2-mutant tumor cells are sensitive to certain drugs, such as mitomycin 
C, platinum salts, and poly(ADP-ribose) polymerase (PARP) inhibitors, which 
stall the progression of replication forks 128. PARPs are key players in DNA 
damage response: they recognize and bind single-strand DNA breaks and other 
DNA lesions and induce the repair process 13, 128. PARP inhibitors work possibly 
by preventing the release of PARPs from the site of DNA damage, which leads to 
stalled replication forks that are normally repaired via HR. In mutant cells lacking 
functional BRCA1 or BRCA2, the inability to repair and restart the stalled 
replication forks via HR leads to programmed cell death, or the DNA damage is 
repaired via a more error-prone mechanism, such as NHEJ, leading to genomic 
instability. The synthetic lethal interaction of PARP with BRCA1 and BRCA2 can 
be exploited in cancer therapy, and the PARP inhibitor olaparib has been shown 
to confer good responses in breast and ovarian cancer patients with BRCA1 or 
BRCA2 mutations 128-130.  
While heterozygous BRCA2 and BRCA1 mutations predispose to breast and 
ovarian cancer, biallelic (i.e. homozygous or compound heterozygous) mutations 
in the genes cause the FA subtypes FANCD1 and FANCS 15, 131. FA is a rare 
chromosomal instability disorder that is characterized by progressive bone 
marrow failure, congenital abnormalities, and an increased risk of cancer, 
particularly leukemia and squamous cell cancers. Cells of FA patients are 
hypersensitive to agents that generate ICLs, such as mitomycin C 15. To date, 
approximately 20 FA genes have been identified. While BRCA2 is a bona fide FA 
gene, biallelic mutations in BRCA1 cause FA-like disorder that lacks some of the 
classical features of FA such as bone marrow failure.  
2.5.1.2 Cancer-predisposition syndromes
Germline mutations in other high-risk genes cause rare dominantly inherited 
cancer-predisposition syndromes where breast and ovarian cancer are among 
the clinical features 2, 3. TP53, PTEN, STK11, CDH1, and NF1 are mainly associated 
with breast cancer and MMR genes with ovarian cancer (Table 1). Mutations in 
these genes are much rarer than BRCA1 or BRCA2 mutations. As most of the 
published studies are based on high-risk families presenting classical cancer-
predisposition syndromes, reliable risk estimates for breast or ovarian cancer 
are lacking due to ascertainment bias 3. Thus, the risks may be overestimated and 
some of the genes might be more appropriately categorized as moderate-risk 
genes. 
Germline TP53 mutations cause Li-Fraumeni syndrome (LFS) characterized 
by a high risk and an early onset of cancer, especially breast cancer, childhood 
sarcomas, brain tumors, and adrenocortical carcinoma 132, 133. Among female 
TP53 mutation carriers, breast cancer is the most common and an increased 
ovarian cancer incidence has also been reported 109. Mai et al. 109 recently 
estimated a high, 85% cumulative risk of breast cancer by age 60. PTEN 
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mutations cause PTEN Hamartoma Tumor syndrome (PHTS) characterized by 
macrocephaly, multiple hamartomas, and increased risks of malignant and 
benign tumors, mainly of the breast, thyroid, and endometrium 110, 134. The 
lifetime breast cancer risk for women with germline PTEN mutations has been 
estimated at 67–85% 110. STK11 mutations predispose to Peutz–Jeghers 
syndrome (PJS) characterized by mucocutaneous pigmentation, gastrointestinal 
polyposis, and an increased risk of cancer, especially gastrointestinal and breast 
cancer 111, 135. The estimated cumulative risk of breast cancer for PJS patients is 
31–54% by age 60 111. An increased risk of ovarian cancer has also been reported, 
but mainly for sex cord ovarian tumors rather than for epithelial ovarian tumors. 
CDH1 mutations predispose to hereditary diffuse gastric cancer and to breast 
cancer, particularly of the lobular subtype 112, 136. The estimated cumulative risk 
of breast cancer for female CDH1 mutation carriers is 42% by 80 years 112. NF1 
mutations predispose to neurofibromatosis type 1, characterized by cutaneous 
neurofibromas, pigmentary changes, and an increased risk of cancer. NF1 
mutations are estimated to confer moderately increased risk of breast cancer 3. 
For women under 40 years, however, some studies have estimated a high, 
approximately 6.5 to 11-fold elevated risk of breast cancer 113, 114. An increased 
risk of ovarian cancer has also been reported 137. 
Mutations in the MMR genes MLH1, MSH2, MSH6, and PMS2 cause Lynch 
syndrome, which predisposes to colorectal cancer as well as to certain 
extracolonic cancers 35-38, 115. For women with Lynch syndrome, gynecological 
cancers are the most common extracolonic malignancies, with an estimated 
lifetime risk of 30–45% for endometrial cancer and 6–14% for ovarian cancer 115. 
The ovarian cancers in women with Lynch syndrome are most commonly 
endometrioid tumors, and they develop at an earlier age than sporadic or 
BRCA1/2-associated ovarian cancers 138. However, they are often diagnosed at an 
earlier stage and thus have a better overall survival. 
TP53 encodes a transcription factor that inhibits cell growth and stimulates 
apoptosis in response to cellular stress, whereas the MMR genes correct base–
base mispairs 2, 17. In contrast, PTEN, STK11, CDH1, and NF1 differ from other 
susceptibility genes as their main function is not in DNA repair or genome 
maintenance. The PTEN phosphatase and the STK11 serine/threonine kinase 
regulate the PI3K–AKT–mTOR and AMPK pathways involved in cell cycle 
regulation, cell metabolism, growth, and survival; CDH1 encodes transmembrane 
glycoprotein E-cadherin, which is involved in cell adhesion; and the 
neurofibromin NF1 is a GTPase activating protein that regulates the RAS 
signaling pathway. 
2.5.2 MODERATE-PENETRANCE GENES
Moderate-penetrance susceptibility genes for breast and ovarian cancer have 
been identified mainly through candidate gene studies in breast or ovarian 
cancer families, but recently, exome and genome sequencing have been 
increasingly utilized for gene discovery 2, 3. Established moderate-penetrance 
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breast cancer susceptibility genes include ATM, CHEK2, and PALB2, whereas 
BRIP1, RAD51C, and RAD51D are ovarian cancer susceptibility genes (Table 4) 2, 
3, 116-122, 139-143.  
ATM is a serine/threonine protein kinase involved in DNA damage checkpoint 
control and HR repair 2. Heterozygous carriers of truncating ATM mutations have 
approximately a 3-fold increased risk of breast cancer 3, 116. Biallelic mutations in 
ATM cause ataxia-telangiectasia, a neurodegenerative disorder with 
immunodeficiency and an increased risk of cancer, particularly leukemia and 
lymphoma 116, 131. The checkpoint kinase CHEK2 is the downstream target of ATM 
in DNA damage checkpoint control and further regulates cell cycle and 
apoptosis 2. Most of the studies on CHEK2 and breast cancer risk are based on a 
truncating mutation c.1100delC which is observed fairly frequently in Northern 
and Eastern European populations but is absent in many other populations 3, 117, 
118. Women with a CHEK2 c.1100delC have approximately a 2 to 3-fold increased 
risk of breast cancer, while for women with a family history of breast cancer, the 
risk is even higher 117, 118. CHEK2 mutations also increase the risk of male breast 
cancer 144. 
The major role of PALB2, BRIP1, RAD51C, and RAD51D is in HR repair of 
DSBs 2. Heterozygous PALB2 mutations increase the risk of breast cancer and 
heterozygous BRIP1, RAD51C, and RAD51D mutations the risk of ovarian cancer, 
whereas biallelic PALB2, BRIP1, and RAD51C mutations cause the FA subtypes 
FANCN, FANCJ, and FANCO, respectively 2, 3, 15, 119-122, 139-141. For women with 
heterozygous pathogenic PALB2 mutations, recent reports have estimated a 5.3-
fold relative risk of breast cancer 3 and a cumulative risk of 35% by age 70 119, 
thus potentially placing PALB2 into the high-risk category. Family history of the 
disease further increases the risk of breast cancer for PALB2 mutation carriers to 
a cumulative risk of 58% by age 70 119. PALB2 mutations also increase the risk of 
male breast cancer, but are not significantly associated with ovarian cancer risk 
120, 144. In contrast, pathogenic BRIP1, RAD51C, and RAD51D mutations confer a 
moderate to high risk of ovarian cancer, but are not significantly associated with 
breast cancer 120-122, 140, 145. Based on a case-control analysis, the estimated 
relative risk of ovarian carcinoma associated with heterozygous BRIP1 mutations 
was 11, whereas a segregation analysis in families yielded an average relative 
risk of 3.4 compared to the general population, and a cumulative risk of 5.8% by 
age 80 120. 
RAD51C was originally proposed as a breast and ovarian cancer susceptibility 
gene by Meindl et al. in 2010 139. Six heterozygous pathogenic RAD51C mutations 
were observed among 480 breast-ovarian cancer families, whereas breast-
cancer-only families and healthy controls did not harbor mutations. In an 
accompanying paper, Vaz et al. reported a homozygous RAD51C missense 
mutation in a patient with FA-like disease 146. Most of the early studies following 
the initial report by Meindl et al. failed to identify clearly pathogenic mutations 
among breast or ovarian cancer patients, indicating that RAD51C mutations are 
very rare 147-150. After the publication of Study I, Loveday et al. confirmed the 
association of RAD51C mutations with ovarian cancer (RR = 5.88, 95% CI = 
Review of the literature 
28 
2.91−11.9, p = 7.65 × 10−7) and estimated a >9% cumulative risk by age 80, 
whereas they observed no evidence of association for breast cancer (RR = 0.91, 
95% CI = 0.45−1.86, p = 0.8) 121. RAD51D was first identified as an ovarian cancer 
susceptibility gene by Loveday et al. in 2011 122. They identified eight deleterious 
RAD51D mutations among 911 breast-ovarian cancer families and one among 
1060 controls, with a higher prevalence of mutations in families with more than 
one ovarian cancer case. Based on a modified segregation analysis, they 
estimated a 6.30-fold (95% CI = 2.86–13.9, p = 4.8 × 10−6) increased risk of 
ovarian cancer for mutation carriers, indicating an approximately 10% lifetime 
risk, but no significant association with breast cancer (RR = 1.32, 95% CI = 0.59–
2.96, p = 0.50) 122. Loveday et al. also demonstrated that RAD51D deficient cells 
are sensitive for PARP inhibitors. The functions of RAD51C and RAD51D are 
described in more detail in section 2.8.  
Heterozygous mutations in the NBN gene have also been associated with an 
increased risk of breast cancer, but currently there is clear evidence for only one 
truncating mutation, c.657_661delACAAA (657del5), which is common in some 
Eastern European populations 3, 151. Biallelic NBN mutations cause Nijmegen 
breakage syndrome, which is characterized by microcephaly, typical facies, 
immunodeficiency, and an increased risk of lymphomas and other cancers 131. 
NBN encodes nibrin, which is part of the MRE11/RAD50/NBN (MRN) complex 
involved in HR repair and checkpoint signaling 2. Recently, we identified a FANCM 
nonsense mutation in an exome sequencing of breast cancer families, and 
subsequent case-control analysis indicated an association especially with triple-
negative breast cancer (TNBC) 152. Similar results have been obtained in other 
studies, but further research is required to draw reliable and more precise risk 
estimates for FANCM mutation carriers. The FANCM protein is important for 
replication-fork protection and ICL repair via the FA pathway, but biallelic 
mutations in the gene do not cause FA syndrome 2, 15, 153, 154. Several other DNA 
repair genes have been suggested as susceptibility genes for breast and ovarian 
cancer, such as the MRN complex genes MRE11 and RAD50 and the FA pathway 
gene FANCC, but the current evidence for these genes is more limited 2, 3. 
2.5.3 LOW-PENETRANCE VARIANTS
Through genome-wide association studies (GWAS), close to 200 low-penetrance 
susceptibility loci for breast cancer and over 30 for ovarian cancer have been 
identified thus far 99, 100. While some of the identified variants are associated with 
both breast and ovarian cancer, some are only associated with specific subtypes, 
such as ER-negative breast cancer or clear cell or mucinous ovarian cancer 99, 155-
158. The low-penetrance variants are typically single-nucleotide polymorphisms 
(SNP) in non-coding regions. Many of them likely function by regulating the 
expression of nearby genes, yet the actual causal variant or the target gene has 
not been identified for most of the susceptibility loci 69, 99, 100, 156. Most of the 
predicted candidate genes function in pathways related to mammary gland 
development, DNA repair, cell cycle control, and ER signaling. 
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The known low-penetrance breast cancer susceptibility loci are estimated to 
account for approximately 18% of the familial relative risk 100. Based on a 
polygenic risk score (PRS) of 77 susceptibility loci, women in the highest 20% of 
the risk distribution are estimated to have a 16.6% lifetime risk of breast cancer, 
while women in the lowest 20% have only a 5.3% lifetime risk 98. Family history 
increases the lifetime risk further to 24.4% for the women in the highest quintile. 
When including all the identified risk SNPs, women in the highest 1% of the 
distribution are estimated to have a 3.5-fold increased risk of breast cancer 100. 
The low-risk SNPs, their combined effects in particular, modify the breast cancer 
risk also in BRCA1/2 and CHEK2 mutation carriers 159-161. Importantly, a high PRS 
puts women with the moderate-penetrance CHEK2 c.1100delC mutation into the 
high-risk category 161. 
For ovarian cancer, the known low-penetrance susceptibility loci are 
estimated to account for approximately 6.4% of the polygenic risk in the 
population 99. PRS based on 17 SNPs was estimated to have low power for risk-
discrimination in the population, but among BRCA1/2 mutation carriers, PRS was 
strongly associated with ovarian cancer risk and its incorporation into risk 
prediction models could allow more precise risk estimates for the mutation 
carriers 160, 162. 
2.5.4 FINNISH FOUNDER MUTATIONS
Isolated founder populations, such as the Finnish population, have a unique 
genetic background and are typically genetically more homogeneous than larger 
and more outbred populations 163. Recent bottlenecks and isolation have led to 
the enrichment of certain alleles, while others have disappeared. In Finns, a 
smaller number of rare variants with MAF < 0.5% has been observed, while loss-
of-function and low-frequency variants with MAFs between 2% and 5% are 
enriched 164, 165.  
The majority of pathogenic mutations in breast and ovarian cancer 
susceptibility genes in the Finnish population are accounted for by only a few 
recurrent founder mutations. Founder mutations have been observed, for 
instance, in BRCA1, BRCA2, PALB2, and FANCM 152, 166, 167. In CHEK2, the 
c.1100delC mutation is most prevalent in Finland and the Netherlands, while it is 
less frequent or absent in other populations 118, 168.  
Despite the seemingly homogeneous genetic profile of Finns, there is also 
substantial genetic variation between Finnish subpopulations 169, 170. Thus, 
certain mutations cluster in different geographical regions and allele frequencies 
may differ between subpopulations. In BRCA1 and BRCA2, for example, several 
founder mutations have been observed which cluster in different geographical 
regions in Finland 166. These mutations explain the majority of all observed 
pathogenic BRCA1/2 mutations in Finland; some of them are unique to the 
Finnish population, while some have been observed elsewhere as well.  
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2.6 INHERITED SUSCEPTIBILITY TO PROSTATE
CANCER
In developed countries, prostate cancer is the most frequently diagnosed cancer 
among men, whereas worldwide it ranks second with an estimated 1.1 million 
cases diagnosed in 2012 1. In Finland, 4855 prostate cancer cases and 921 deaths 
occurred in 2015 4. Globally, over 300 000 prostate cancer deaths were estimated 
to have occurred in 2012 1. The prognosis for prostate cancer is good, with a 94% 
relative 5-year survival ratio in Finland 4. 
Even though epidemiological studies have suggested environmental and 
lifestyle risk factors for prostate cancer, no such risk factors have been 
convincingly linked to prostate cancer 171, 172. Family history, however, is an 
established risk factor: first-degree relatives of men with prostate cancer have an 
approximately two-fold increased risk. Heritability of prostate cancer is 
estimated to be as high as 57% 68. While only a few rare, high-penetrance 
mutations for prostate cancer have been identified, numerous common, low-risk 
variants have been recognized 171, 172. To date, the transcription factor HOXB13 
remains the only moderate to high-risk susceptibility gene identified that 
predominantly predisposes to prostate cancer 171-173. A pathogenic missense 
mutation, G84E in the HOXB13 gene, is particularly frequent in the Finnish 
population 174. Mutations in the breast cancer susceptibility gene BRCA2 also 
increase the risk of prostate cancer and predispose to a more aggressive disease 
171, 172, 175, 176. Data for BRCA1 is less clear, with some evidence for moderately 
increased prostate cancer risk 171, 172, 176, 177. Several other breast or ovarian 
cancer susceptibility genes with a function in DNA repair, including PALB2, 
CHEK2, and BRIP1, have also been investigated 171, 172, 176. For these genes, there 
is some evidence of association with prostate cancer, but the data is more 
inconclusive. Nevertheless, 11.8% of men with metastatic prostate cancer harbor 
germline mutations in DNA repair genes, with BRCA2 mutations being the most 
frequent 176. More than 100 low-risk loci for prostate cancer predisposition have 
been identified through GWAS, with some shared loci between breast, ovarian, 
and prostate cancer 155, 178, 179. Together, the known risk loci are estimated to 
explain approximately 39% of the familial risk of prostate cancer 179. 
2.7 INHERITED SUSCEPTIBILITY TO COLORECTAL
CANCER
Colorectal cancer is the second most common cancer among women and the third 
among men, both worldwide and in more developed countries, with an estimated 
1.4 million cases diagnosed in the world in 2012 1. In Finland, 1014 female and 
981 male colon cancers as well as 460 female and 708 male rectum cancers were 
diagnosed in 2015 4. Globally, almost 700 000 colorectal cancer deaths were 
estimated to have occurred in 2012, and in Finland, 1197 colorectal cancer 
deaths were observed in 2015 1, 4. The prognosis of colorectal cancer has been 
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improving in many Western countries, with almost 65% 5-year relative survival 
ratios observed in high-income countries 180. In Finland, the 5-year relative 
survival is 66% 4. 
Colorectal cancer incidence has been linked to the Western lifestyle, with 
potentially modifiable risk factors such as smoking, high consumption of alcohol 
and red or processed meat, obesity, and diabetes accounting for a large 
proportion of the disease burden at the population level 180. Inflammatory bowel 
disease and family history of colorectal cancer are stronger, if rarer, risk factors. 
First-degree relatives of colorectal cancer patients have an approximately two-
fold increased risk. While colorectal cancer is estimated to have a high 40% 
heritability, the estimates for colon and rectal cancers individually are relatively 
smaller than for other cancer types, at 15% and 14%, respectively 68, 181.  
A small proportion of colorectal cancers are due to rare, high-penetrance 
mutations in genes that predispose to hereditary syndromes with early-onset 
colorectal cancer 38, 182. The most common form is Lynch syndrome, which is 
caused by mutations in the MMR genes MLH1, MSH2, MSH6, and PMS2 35-38, 182. A 
hallmark of Lynch syndrome is microsatellite instability resulting from defective 
mismatch repair 38, 182. The most severe form of polyposis syndromes, familial 
adenomatous polyposis, is caused by highly-penetrant mutations in the APC gene 
involved in the Wnt signaling pathway, which controls cell division, adhesion, 
and migration 38, 182, 183. In contrast to the other, dominantly inherited syndromes, 
MUTYH-associated polyposis is a recessive form of adenomatous polyposis 
caused by biallelic mutations in the MUTYH gene, which is involved in base-
excision repair 182, 184. Mutations in the DNA polymerase genes POLE and POLD1 
cause polymerase-proofreading-associated polyposis characterized by 
hypermutated, but microsatellite-stable colorectal tumors 182, 185. Mutations in 
the TGFβ/BMP signaling pathway genes SMAD4 and BMPR1A predispose to 
juvenile polyposis syndrome 182, 186, 187. Colorectal cancer is also part of the 
clinical spectrum of PHTS and PJS, caused by mutations in the PTEN and STK11 
genes, respectively 38, 134, 135, 182. However, mutations in the known susceptibility 
genes explain less than half of the cases of familial colorectal cancer 188. Some of 
the excess familial risk for colorectal cancer is likely explained by unidentified 
high-risk genes, and some by common low-risk variants 180, 188. To date, over 40 
low-risk loci have been identified through numerous GWAS 182, 189. 
2.8 RAD51 PARALOGS
The five human RAD51 paralogs – RAD51B, RAD51C, RAD51D, XRCC2, and 
XRCC3 – play an essential role in DNA damage repair via HR 14. HR is an error-
free mechanism to repair DSBs in mammalian cells as it uses the homologous 
DNA sequence on the sister chromatid as a template. HR is also crucial for the 
repair and restart of stalled replication forks. In DSB repair, the DNA ends at the 
break site are first processed to reveal single-stranded DNA, and the repair 
process is initiated by the binding of RAD51 recombinase. The RAD51 monomers 
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assemble around the single-stranded DNA to form a nucleoprotein filament that 
catalyzes strand invasion and pairing with the intact homologous DNA molecule 
to form heteroduplex DNA. The RAD51 paralogs, along with BRCA2, help to 
recruit the RAD51 recombinase to the break site. RAD51 paralog deficient cells 
are sensitive to DNA damaging agents and lack the ability to form RAD51 foci in 
response to ionizing radiation 14, 190. Disruption of any of the Rad51 paralog genes 
in mice causes early embryonic lethality and accumulation of unrepaired DNA 
damage. 
The RAD51 paralogs form two major complexes in cells: the BCDX2 complex 
formed by RAD51B, RAD51C, RAD51D, and XRCC2, and the CX3 complex formed 
by RAD51C and XRCC3 (Figure 1) 191. The BCDX2 complex has been shown to act 
in the early stage of HR – upstream of the RAD51 recruitment to the damage site 
– whereas the CX3 complex acts downstream of RAD51 recruitment 192. The 
RAD51 paralogs share a highly conserved central domain with Walker A and 
Walker B consensus motifs, which confer ATP binding and hydrolysis 
activities 193. An intact β-sheet in the C-terminus of the paralogs is needed for a 
proper folding of the proteins 194. All paralogs, except XRCC2, which lacks the N-
terminal domain, have a linker region between N and C-terminal domains, which 
is important for the interactions between the paralogs (Figure 1) 194. 
 
Figure 1 Schematic representation of the BCDX2 and CX3 complexes and the RAD51
paralogs. Adapted from Suwaki et al. 2011 14. Reprinted with permission from Elsevier.
2.8.1 RAD51C
RAD51C is the only RAD51 paralog that is detected in both the BCDX2 and CX3 
complex (Figure 1) and it also forms additional sub-complexes with RAD51B, 
XRCC3, and RAD51D as well as with both RAD51D and XRCC2 together 14, 191. It 
also binds to PALB2 and forms a complex with PALB2, BRCA2, and RAD51 195. 
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The RAD51C gene, located on chromosome 17, encodes a 376-amino-acid long 
protein 196. In addition to the conserved N and C-terminal domains shared by the 
paralogs, RAD51C has a nuclear localization signal in the C-terminus, which is 
absent in RAD51 and most of the other paralogs 14, 197. While the C-terminal 
region is required for the nuclear localization and RAD51 paralog complex 
formation, the N-terminal region of RAD51C is necessary for interaction with an 
E3 ubiquitin ligase RAD18, which is involved in DNA damage signaling 194, 197, 198. 
RAD18 binds to the break site on DNA and links DNA damage checkpoint 
response to DNA repair via its direct interaction with RAD51C. Loss of the 
RAD51C N-terminal region confers cells sensitive to DNA damaging agents and 
causes defects in HR, but does not affect RAD51 paralog complex formation. 
RAD51C is also required for CHEK2 activation and cell-cycle arrest in response 
to DNA damage 199, 200.  
RAD51C has a role in both the early and late stages of HR 14. The early role of 
the RAD51 paralogs is to aid RAD51 nucleoprotein filament assembly, while the 
late role of RAD51C is in the processing of Holliday junctions, the intermediate 
crossover structures between the damaged DNA and the undamaged 
homologous chromosome 14, 201. Consistent with both an early and a late function, 
RAD51C accumulates at DNA damage sites together with RAD51, and persists 
after RAD51 has disassembled 199. In addition to the repair of DSBs, RAD51C is 
also required for the downstream HR step of ICL repair via the FA pathway 200. 
Other roles for RAD51C in genome maintenance include protection of stalled 
replication forks and maintenance of correct centrosome numbers in 
mitosis 202, 203. 
Rad51c has been shown to function as a tumor suppressor in mice 204, 205. 
However, deletion of Rad51c alone is not sufficient to drive tumorigenesis, 
whereas deletion of Rad51c together with Trp53 leads to tumor progression 206. 
Studies in hamster cells indicate that Rad51c haploinsufficiency causes increased 
DNA damage sensitivity and genomic instability, and thus may contribute to 
tumorigenesis 207. In ER-positive breast cancer cells, estrogen has been shown to 
regulate RAD51C expression and to induce the formation of nuclear RAD51C 
foci 208. 
2.8.2 RAD51D
The RAD51D gene is located on chromosome 17 and encodes a 328-amino-acid 
long protein 209. RAD51D has been shown to act in the early steps of HR repair 
and is part of the BCDX2 complex 192. The N-terminal domain of RAD51D binds 
to XRCC2 and single-stranded DNA, while the C-terminal domain binds 
RAD51C 194. Moreover, the conserved ATPase motif is required for the 
interaction of RAD51D with RAD51C and XRRC2 and for proper HR 
function 210, 211. RAD51D also binds to the BLM helicase involved in the 
processing of Holliday junctions 212. The RAD51D-XRCC2 complex can stimulate 
the disruption of synthetic Holliday junctions by BLM, indicating that RAD51D 
also plays a role in the late stages of HR. In addition to its role in DSB repair, 
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RAD51D is needed for telomere maintenance through HR 213. Telomeres protect 
chromosome ends from degradation and fusion; RAD51D-deficient cells show 
telomere shortening, loss of telomere capping, and increased levels of 
chromosomal aberration. Furthermore, RAD51D-deficient mouse cells display 
extensive chromosome instability and decreased radiation-induced RAD51-
focus formation and are hypersensitive to DNA damaging agents 214. 
2.9 RAD54L
RAD54L is another DNA repair protein that functions in HR together with 
RAD51 215. The RAD54L gene encodes a DNA translocase with double-stranded 
DNA-dependent ATPase activity, that belongs to the Swi2/Snf2 family of motor 
proteins. RAD54L functions in DNA repair by stabilizing the interaction of RAD51 
with single-stranded DNA, by promoting strand invasion, and by removing 
RAD51 from the double-stranded heteroduplex DNA 14, 215, 216. The disassociation 
of RAD51 from the double-stranded DNA after strand exchange is important in 
order to make the 3’ ends of the invading single-stranded DNA accessible for the 
DNA polymerase to use as primers for the DNA repair synthesis. In addition to 
removing RAD51 from the heteroduplex DNA during damage repair, RAD54L 
also prevents the accumulation of RAD51 on undamaged DNA. RAD51 is often 
expressed at high levels in tumors, which can lead to toxic formation of RAD51 
foci on undamaged chromatin. Depletion of RAD54L and its paralog RAD54B in 
tumor cells leads to accumulation of RAD51 foci on undamaged DNA, which 
further leads to defects in replication and chromosome segregation 216. Given its 
role in the HR repair of DNA damage, RAD54L is a potential candidate gene for 
breast and ovarian cancer susceptibility. 
2.10 NEXT-GENERATION SEQUENCING IN CANCER
RESEARCH AND DIAGNOSTICS
The development of NGS methods has revolutionized genomics and cancer 
research as they allow a much cheaper and quicker way of sequencing DNA or 
RNA than the traditional Sanger method 217. In NGS, vast numbers of short reads 
are sequenced in parallel. Various technologies exist, but they all rely on the 
preparation of sample libraries from input DNA or RNA. The different 
technologies can be applied to whole-genome sequencing, or to whole-exome 
sequencing, which is restricted to the protein-coding part of the genome. In more 
targeted applications, selected regions of the genome are first amplified by PCR, 
which allows analysis of a panel of disease genes, for example. 
In the research setting, new putative breast and ovarian cancer susceptibility 
genes have been discovered through whole-exome and targeted sequencing 
studies 2. In a clinical diagnostic setting, gene panels are now increasingly 
utilized, as they allow a rapid and cost-effective analysis of multiple genes 
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simultaneously 3. Clinical genetic testing of high-risk women, such as familial or 
early-onset breast and ovarian cancer patients, was long restricted to the BRCA1 
and BRCA2 genes. As many more susceptibility genes are now recognized, these 
single-gene tests would leave numerous women without a genetic diagnosis 
despite their potentially actionable mutations. Moreover, in some families more 
than one risk variant segregates. In recent gene-panel studies, mutations in genes 
other than BRCA1 and BRCA2 have been detected in approximately 4–6% of 
hereditary breast and ovarian cancer patients 218. Thus, gene panels allow more 
comprehensive testing than single-gene tests, allowing more women to receive a 
genetic diagnosis. However, many commercially available gene panels include 
numerous cancer predisposition genes of which only some have clinical utility 
for breast or ovarian cancer 3. To have clinical validity for breast cancer, Easton 
et al. estimated that there is sufficient evidence of association only for BRCA1, 
BRCA2, TP53, CDH1, PTEN, STK11, NF1, PALB2, CHEK2, ATM, and NBN 3. For 
RAD51C, RAD51D, and BRIP1, there is currently clear evidence of association with 
ovarian cancer 3, 120-122 (I, II). Missense variants are typically more difficult to 
interpret than protein-truncating mutations, and variants of unknown 
significance are often discovered even in the established risk-genes. Thus, much 
more research is needed to provide more precise risk estimates for a large 
number of putative susceptibility genes included in the gene panels. 
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3 AIMS OF THE STUDY
The aim of this thesis was to find and characterize new cancer-predisposing 
mutations in the RAD51 paralogs RAD51C and RAD51D as well as in the RAD54L 
gene, and to investigate high-risk breast and ovarian cancer patients with a gene 
panel. The specific aims of the study were: 
 
1. To identify RAD51C germline mutations in Finnish breast and ovarian 
cancer families and to determine their role in breast and ovarian cancer 
predisposition. 
2. To identify germline mutations in the RAD51D and RAD54L genes in 
breast and ovarian cancer families and to determine whether the 
identified mutations are associated with breast, ovarian, prostate, and 
colorectal cancer risk in the Finnish population. 
3. To determine the role of the Finnish RAD51C founder mutations in 
prostate and colorectal cancer predisposition. 
4. To determine the mutation spectrum of the known breast and ovarian 
cancer susceptibility genes in high-risk breast and ovarian cancer patients 
with a gene panel and to characterize the identified RAD51C duplication 
and its role in breast and ovarian cancer predisposition. 
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4 MATERIALS AND METHODS
4.1 SUBJECTS
In Studies I and II, familial breast and ovarian cancer patients from the Helsinki 
region of Finland were first screened for germline variation in the RAD51C 
(n = 277) and RAD51D and RAD54L genes (n = 95). The identified truncating 
RAD51C mutations and the missense variant were further genotyped in 
unselected (n = 884) and additional familial breast cancer patients (n = 491), 
unselected ovarian cancer patients (n = 409), and population controls (n = 1279) 
from Helsinki (I). The truncating mutations were also genotyped in breast cancer 
patients (n = 686) and population controls (n = 807) from the Tampere region (I) 
as well as in prostate (n = 1083) and colorectal cancer cases (n = 802) from 
Tampere and southeastern Finland, respectively (III). The identified RAD51D 
mutation was genotyped in unselected breast cancer patients (n = 849), 
additional familial breast or ovarian cancer patients (n = 680), unselected 
ovarian cancer patients (n = 541), and population controls (n = 1287) from the 
Helsinki region, in breast (n = 691) and prostate cancer patients (n = 1094) and 
population controls (n = 815) from the Tampere region, as well as in colorectal 
cancer patients (n = 980) from southeastern Finland (II). 
In Study IV, 95 high-risk breast or ovarian cancer patients were tested with a 
gene panel. The identified RAD51C duplication was further screened in 
unselected breast (n = 1729) and ovarian cancer patients (n = 553), additional 
familial breast or ovarian cancer patients (n = 800), and population controls 
(n = 1273) from the Helsinki region.  
Relatives with samples available from the mutation carrier families were 
analyzed for the respective mutations (I, II, IV). All samples consisted of genomic 
DNA isolated from peripheral blood of the subjects, except for 124 samples from 
unselected ovarian cancer patients, which were tumor DNA, and for the 
colorectal cancer samples, which were genomic DNA isolated from blood or 
normal mucosa. 
4.1.1 HELSINKI BREAST AND OVARIAN CANCER SERIES (I, II, IV)
The unselected breast cancer patient series from Helsinki consisted of two 
cohorts collected at the Helsinki University Hospital Department of Oncology in 
1997–1998 and 2000 (n = 884) 106, 219 and the Department of Surgery in 2001–
2004 (n = 886) 220. The series cover 79% and 87% of all consecutive, newly 
diagnosed breast cancer patients, unselected for age or family history, during the 
collection periods. Only invasive female patients were included in the analyses. 
Additional familial breast and ovarian cancer patients were ascertained at the 
Helsinki University Hospital Department of Oncology through systematic 
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screening (1993-) and at the Department of Clinical Genetics through genetic 
counselling in an ongoing collection 168, 220, 221.  
After combining patients with a positive family history from the unselected 
series (n = 383) and the additional familial patients, 1149 patients were included 
in the familial cohort. These comprised 592 families with at least three breast or 
ovarian cancer cases among first or second-degree relatives, 549 families with 
two breast or ovarian cancers in first-degree relatives, and 8 families with at least 
two ovarian cancers among first-degree relatives with no known family history 
of breast cancer. The patients had been tested negative for BRCA1/2 mutations 
and their genealogies confirmed through population registries and all cancer 
diagnoses in the Finnish Cancer Registry or in hospital records. Information on 
the tumor histology, grade, size, nodal status, distant metastases at diagnosis, and 
ER and PR-status was collected from pathology reports 222. HER2-status was 
based on immunohistochemistry and on gene amplification with chromogenic in 
situ hybridization on tumor microarrays (CISH), as previously described 223.  
The unselected ovarian cancer patient series was collected at the Helsinki 
University Hospital Department of Obstetrics and Gynecology in 1998–2006. 
Blood samples from 233 patients were retrospectively collected in 1998 as 
previously described 107. The patients had been treated for invasive epithelial 
ovarian carcinoma at the Helsinki University Hospital between 1989 and 1998 
and the samples were collected during routine follow-up visits to the clinic in 
1998 from patients who were still alive. Additional blood or tumor tissue samples 
were prospectively collected from 320 patients treated for ovarian carcinoma at 
the Helsinki University Hospital Department of Obstetrics and Gynecology 
between 1998 and 2006. Up to 429 genomic and 124 tumor DNA samples were 
included in the analyses. 
4.1.2 GENE-PANEL SEQUENCING SAMPLES (IV)
A total of 95 high-risk breast or ovarian cancer patients referred to clinical 
genetic testing were studied with a gene panel. The patients were ascertained at 
the Helsinki University Hospital Department of Clinical Genetics and they fulfilled 
the following criteria: at least three breast or ovarian cancer cases among first or 
second-degree relatives, proband included (n = 35), two breast or ovarian cancer 
cases among first-degree relatives, proband included (n = 23), male breast cancer 
cases (n = 5), early-onset breast cancer cases diagnosed at the age of 40 or 
younger (n = 18), TNBC cases diagnosed at the age of 50 or younger (n = 10), or 
patients who were affected with breast and ovarian (n = 3) or breast and 
colorectal cancer (n = 1) and who had a family background of other cancers. 
Information on family history was collected from patient interviews whereafter 
most of the cancer cases were verified from clinical records. Male relatives were 
excluded when calculating the degree of relationship for the breast cancer 
families. Altogether 13 patients had been previously screened negative for the 
Finnish BRCA1/2 founder mutations and 4 patients for the full BRCA1/2 genes. In 
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addition, three patients had a family member previously screened negative for 
the BRCA1/2 founder mutations or the full genes.  
4.1.3 TAMPERE BREAST CANCER SERIES (I, III)
An unselected breast cancer series was collected at Tampere University Hospital 
and comprised 408 consecutive patients recruited between 1997 and 1999 and 
an additional 336 incident cases recruited between 1996 and 2004 106, 220.  
4.1.4 PROSTATE CANCER SERIES (II, III)
An unselected series of 905 prostate cancer patients was collected in the 
Pirkanmaa Hospital District. The patients had been diagnosed with prostate 
cancer at the urology out-patient clinic at Tampere University Hospital between 
1980 and 2008. An additional 189 prostate cancer families were collected as 
previously described 224. The families included at least two prostate cancer 
patients, and the youngest case from each family was included in the analyses.  
4.1.5 COLORECTAL CANCER SERIES (II, III)
The colorectal cancer patient series was collected at nine large regional hospitals 
in southeastern Finland in 1994–1996 (509 consecutive patients) and 1996–
1998 (535 consecutive patients), as previously described 225, 226. Altogether 158 
patients had a family background of colorectal cancer.  
4.1.6 POPULATION CONTROLS (I, II, IV)
The population controls were healthy female blood donors from the same 
geographic regions. 
4.2 MUTATION ANALYSIS
4.2.1 GENE-PANEL SEQUENCING (IV)
Ten genes (BRCA1, BRCA2, CDH1, CHEK2, PTEN, STK11, TP53, PALB2, RAD51C, 
and RAD51D) were analyzed with gene-panel sequencing in 95 breast or ovarian 
cancer patients. The SureSelectXT Custom 3-5.9 Mb library kit (Agilent 
Technology) was used for DNA capture and the sequencing was performed on 
the Illumina HiSeq 2500 (Illumina) at Lund University. The sequencing covered 
the complete genes, including the introns as well as a 150 kilobase pair (kb) 
upstream and downstream sequence for BRCA1 and BRCA2, 50 kb for CDH1, 
CHEK2, PTEN, STK11, and TP53, and 20 kb for PALB2, RAD51C, and RAD51D. 
Identified variants were annotated with snpEff 227and Annovar 228 for their effect 
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on protein-coding transcripts, and only protein-truncating mutations (i.e. 
nonsense, splicing and frameshift indel mutations) and pathogenic missenses in 
the 10 studied genes were considered in this study. Copy number variants (CNV) 
were identified at Lund University using an in-house method based on the 
number of read pairs in short windows over the target regions. In addition, large 
genomic changes in BRCA1 and BRCA2 were investigated by Multiplex Ligation-
dependent Probe Amplification (MLPA). Pathogenic mutations in the studied 
genes were verified with Sanger sequencing. 
4.2.2 SANGER SEQUENCING (I, II, IV)
The RAD51C gene was screened for germline mutations by Sanger sequencing in 
277 and the RAD51D and RAD54L genes in 95 familial breast or ovarian cancer 
patients (I, II). The exact size and location of the RAD51C ex1-7 duplication, 
identified in the CNV analysis of the gene-panel samples, was characterized by 
Sanger sequencing of the index patient (IV).  
The DNA samples were amplified with polymerase chain reaction (PCR) using 
standard protocols. The PCR products were purified with ExoSAP-IT 
(Affymetrix) or A’SAP (ArcticZymes) enzymes. ABI BigDye Terminator 3.1 Cycle 
Sequencing kit (Applied Biosystems) was used for sequencing reactions and the 
sequencing was performed at the Institute for Molecular Medicine Finland 
(FIMM), University of Helsinki, using a 3730xl DNA Analyzer (Applied 
Biosystems). Sequence chromatograms were analyzed with FinchTV (Geospiza) 
and Variant Reporter (Applied Biosystems). 
4.2.3 GENOTYPING (I–IV)
The identified RAD51C and RAD51D point mutations were genotyped by direct 
sequencing as described above or by TaqMan real-time-PCR with Custom 
TaqMan SNP genotyping assays and TaqMan Genotyping MasterMix (Applied 
Biosystems). 
The RAD51C duplication was genotyped with PCR assay. The DNA samples 
were amplified with a forward primer in the RAD51C intron 7 upstream of the 
duplication breakpoint and a reverse primer in the duplicated sequence 
upstream of the RAD51C gene. A second reverse primer in the non-duplicated 
region in intron 7 was added to monitor the success of the PCR reaction. The PCR 
products were run on a 2% agarose gel and two bands were seen for the 
duplication carriers and one band for the non-carriers. All carriers were 
confirmed with a second PCR. 
4.3 LOSS-OF-HETEROZYGOSITY ANALYSIS (I, II)
Breast or ovarian tumors from nine RAD51C mutation carriers and four RAD51D 
mutation carriers were analyzed for loss-of-heterozygosity (LOH). Tissue cores 
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were punched from paraffin-embedded tumor samples and DNA was isolated by 
standard phenol-chloroform method or with ArchivePure DNA Blood kit 
(5Prime) followed by PCR and direct sequencing. The sequencing results were 
compared with heterozygous germline DNA isolated from blood. 
4.4 SPLICING ANALYSIS (I)
Total RNA from blood samples of two RAD51C c.837+1G>A mutation carriers was 
isolated using PAXgene Blood RNA kit (Pre-Analytix) and converted into single-
stranded complementary DNA (cDNA) with a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). The cDNA was amplified by PCR using 
primers specific for RAD51C exons 3 and 8. The PCR products were analyzed on 
2% agarose gel and extracted with MinElute Gel Extraction kit (Qiagen) followed 
by Sanger sequencing. A cDNA sample from a control subject negative for the 
mutation was amplified by PCR followed by direct sequencing. 
4.5 HAPLOTYPE ANALYSIS (I, II)
To define whether the mutation carrier families have a common ancestry, seven 
and eight SNP markers located within and around the RAD51C and RAD51D 
genes, spanning 34 and 95 kb, respectively, were screened by Sanger sequencing 
in family members with available DNA samples from the mutation carrier 
families. The haplotype analysis was performed for eight individuals from four 
RAD51C c.93delG families, six individuals from three RAD51C c.837+1G>A 
families, and ten individuals from four RAD51D c.576+1G>A families. Haplotypes 
were constructed manually. 
4.6 GENE-EXPRESSION AND mRNA ANALYSIS (IV)
The RAD51C expression was studied in lymphoblastoid cell lines (LCL) of RAD51C 
ex1-7 duplication carriers and non-carriers. Samples of four female breast cancer 
patients from the RAD51C ex1-7 duplication family, including three duplication 
carriers and one non-carrier, were compared to a reference sample from an 
unrelated healthy non-carrier woman. The LCLs were cultured in RPMI (Lonza) 
supplemented with 10% FBS (Gibco), 1% glutamine, and 1% streptomycin-
penicillin at +37°C in a humidified chamber with 5% CO2. Gene-expression 
analysis was performed with Cells-to-CT 1-Step TaqMan Kit (Ambion) and 
TaqMan gene-expression assays (Applied Biosystems) according to the 
manufacturers’ protocols. To ensure that no genomic DNA would be detected in 
the expression analysis, the cells were treated with DNase and then TaqMan 
gene-expression assays that bind to exon boundaries were selected. Two RAD51C 
gene-expression assays (Hs00427442_m1 and Hs00980059_m1) that bind to the 
exon 1-2 and 8-9 junctions were used to measure RAD51C expression and an 
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ACTB assay (Hs99999903_m1) was used as an endogenous control. Four 
independent experiments were performed with three technical PCR replicates. 
The relative expression was quantified using the comparative CT method.  
The mRNA produced from the duplication was further characterized at Mayo 
Clinic. Briefly, total RNA was extracted from LCLs of three carriers and two non-
carrier controls with RNeasy Plus Mini kit (Qiagen) and the RNA was converted 
into cDNA with SuperScript III RT-PCR kit (Invitrogen). The carrier and non-
carrier cDNA templates were amplified with PCR using primers in RAD51C exons 
4 and 7 or at the exon 4-5 junction and intron 7. A human genomic DNA control 
was included to confirm that the PCR product was not from genomic DNA. The 
PCR products were analyzed on agarose gel. 
4.7 IN SILICO PREDICTION TOOLS AND ONLINE
DATABASES (I, II, IV)
The effect of the RAD51D c.576+1G>A mutation on splicing was evaluated with 
the Human Splicing Finder 229 and MaxEntScan 230 prediction tools (II). 
ClinVar 231 and HGMD 232 databases were searched for clinical significance 
interpretations for the PTEN and TP53 missense mutations observed in Study IV. 
The Exome Aggregation Consortium (ExAC) and Genome Aggregation Databases 
(GnomAD) were searched for variant frequency information 233-235. 
4.8 STATISTICAL METHODS (I, II, IV)
Statistical analyses were performed with SPSS and R software. To study the 
association of the mutations with cancer risks, odds ratios with 95% confidence 
intervals were estimated with logistic regression and two-sided p-values were 
calculated using Fisher’s exact test. Student’s t-test was used to calculate the p-
value for comparing the age at onset between mutation carriers and non-carriers 
and to evaluate the difference in the RAD51C expression. A p-value of <0.05 was 
considered statistically significant. 
4.9 ETHICAL ASPECTS
The studies were approved by the Ethics Committee of Helsinki University 
Hospital and by the ethics committees of the other respective hospitals. All 




5.1 IDENTIFICATION OF RAD51C AND RAD51D
MUTATIONS (I, II)
One frameshift deletion c.93delG (p.Phe32SerfsX8) and one splicing mutation 
c.837+1G>A were identified in the Sanger sequencing of the RAD51C gene in 277 
familial breast or ovarian cancer patients (Table 5). The c.93delG deletion was 
predicted to lead to a premature stop-codon in the first exon of the RAD51C gene, 
whereas the c.837+1G>A mutation disrupts the conserved 5’ splice donor site of 
exon 5. We also detected one rare RAD51C missense variant c.790G>A, which was 
previously identified in breast and ovarian cancer families by Meindl et al. 139.   
In the sequencing of the RAD51D gene in 95 patients, one splicing mutation, 
c.576+1G>A, which abolishes the splice donor site in exon 6, was observed, 
whereas no pathogenic mutations were detected in RAD54L (Table 5). In 
addition, several polymorphisms were identified in all three genes.  
5.2 FREQUENCIES OF RAD51C AND RAD51D POINT
MUTATIONS (I, II, III)
5.2.1 TRUNCATING RAD51C AND RAD51D MUTATIONS (I, II, III)
Genotyping of the identified protein-truncating RAD51C mutations c.93delG and 
c.837+1G>A and the RAD51D mutation c.576+1G>A in additional breast, ovarian, 
prostate, and colorectal cancer patients and population controls revealed six 
RAD51C and five RAD51D mutations among cases and two RAD51C and one 
RAD51D mutations among controls. 
After combining the results of the initial sequencing and the subsequent 
genotyping, eight RAD51C mutations were detected among the patients in the 
Helsinki series (Table 6). All the mutation carriers had either a personal or family 
history of ovarian cancer. Each mutation was found in one breast-ovarian cancer 
family as well as in one ovarian cancer family but neither one was detected 
among breast-cancer-only families or among unselected breast cancer patients. 
Two c.93delG deletions and two c.837+1G>A splicing mutations were detected in 
the unselected ovarian cancer series with a combined frequency of 1% (OR = 
6.31, 95% CI = 1.15-34.6, p = 0.033 compared to population controls). The highest 
mutation frequency, 25%, was among ovarian cancer families (p = 0.0002 
compared to population controls). Compared to the unselected ovarian cancer 
patients, the mutations were significantly more frequent among the ovarian 
cancer families (p = 0.005). The splicing mutation c.837+1G>A was not present 




Table 5. Polymorphisms and mutations identified in the screening for the RAD51C,
RAD51D, and RAD54L genes. Mutations selected for further genotyping are highlighted in
bold.
DNA change Protein change rs-number AA Aa aa MAF gnomAD-FIN
RAD51C (transcript NM_058216)
c.-26CT - rs12946397 175 82 20 22.0% 26.1%
c.93delG p.Phe32Serfs rs730881942 275 2 0 0.36% 0.02%
c.790G>A p.Gly264Ser rs147241704 276 1 0 0.18% 0.06%
c.837+1G>A - rs760235677 275 2 0 0.36% 0.01%
c.859A>G p.Thr287Ala rs28363317 276 1 0 0.18% 0.05%
c.904+34T>C - rs28363318 135 115 27 30.5% 30.0%
RAD51D (transcript NM_002878)
c.82+128C>T - rs28363258 93 2 0 1.05% 1.72%
c.234C>T p.Ser78Ser rs9901455 78 17 0 8.95% 11.1%
c.494G>A p.Arg165Gln rs4796033 71 23 1 13.2% 16.9%
c.576+1G>A - rs781161543 93 2 0 1.05% 0.004%
c.903+53C>T - rs45496096 90 5 0 2.63% 1.40%
RAD54L (transcript NM_003579)
c.-112A>G - rs17102080 92 3 0 1.58% 1.52%
c.62A>G p.Asp21Gly rs28363192 93 2 0 1.05% 1.67%
c.408-157A>C - rs2295465 82 13 0 6.84% 10.5%
c.604C>T p.Arg202Cys rs28363218 94 1 0 0.53% 0.31%
c.767-57G>T - rs61239976 89 6 0 3.16% -
c.1610+45C>T - rs118091259 93 2 0 1.05% 0.64%
c.1759C>T p.Arg587Trp rs150315374 90 5 0 2.63% 2.95%
c.2190C>T p.Ala730Ala rs1048771 83 12 0 6.32% 9.11%
c.2213G>A p.Arg738His rs28910278 94 1 0 0.53% 1.73%
DNA change = DNA-level variant coding according to HGVS nomenclature; 
Protein change = protein-level variant coding according to HGVS nomenclature; 
AA = number of common homozygotes; Aa = number of heterozygotes; aa = 
number of rare homozygotes; MAF = minor-allele frequency among the 
sequenced patients; gnomAD-FIN = minor-allele frequency among the Finnish 




Table 6. Frequencies of the protein-truncating RAD51C c.93delG and c.837+1G>A
mutations in different patient groups.
Total wt (%) mut (%) p-value OR (95% CI)
Helsinki series
Population controls 1279 1277 (99.8%) 2 (0.2%)
Familial BC 803 803 (100%) 0 (0.0%) 0.526
Familial BC+OC 158 156 (98.7%) 2 (1.3%) 0.062 8.19 (1.14-58.5)
≥3 affected 96 94 (97.9%) 2 (2.1%) 0.026 13.6 (1.89-97.6)
2 affected 62 62 (100%) 0 (0.0%) 1
Unselected BC 833 833 (100%) 0 (0.0%) 0.522
Familial OC 8 6 (75.0%) 2 (25.0%) 0.0002 213 (25.6-1769)
Unselected OC 409 405 (99.0%) 4 (1.0%) 0.033 6.31 (1.15-34.6)
Any OC a 575 567 (98.6%) 8 (1.4%) 0.002 9.01 (1.91-42.6)
Tampere series
Population controls 807 807 (100%) 0 (0.0%)
Unselected BC 686 684 (99.7%) 2 (0.3%) 0.211
Prostate cancer 1083 1083 (100%) 0 (0.0%) 0.503
Colorectal cancer 802 802 (100%) 0 (0.0%) 0.526
a Any OC includes patients with personal or family history of OC; BC = breast 
cancer, OC = ovarian cancer, wt = wild type, mut = carrier of c.93delG or 
c.837+1G>A mutation. 
 
Altogether seven RAD51D c.576+1G>A mutations were identified among patients 
and one among controls in the Helsinki series after combining the two stages of 
mutation testing (Table 7). Five of the mutation carrier patients had a personal 
or family history of ovarian cancer (OR = 9.16, 95% CI = 1.07-78.6, p = 0.024 
compared to controls). The highest mutation frequency of 2.9% was among 
breast-ovarian cancer families with at least three affected family members (OR = 
37.8, 95% CI = 3.90-367, p = 0.002). In the unselected cohorts, one breast cancer 
patient and three ovarian cancer patients carried the mutation. The mutation-
positive unselected breast cancer patient and one of the unselected ovarian 
cancer patients are also included in the breast-ovarian cancer families. 
In the Tampere series, two RAD51C c.93delG mutations and one RAD51D 
c.576+1G>A mutation were detected among the breast cancer patients, whereas 
none of the mutations were observed in the controls (Tables 6 and 7). No 
mutations were detected among the prostate or colorectal cancer patients. The 
results suggest that the protein-truncating RAD51C and RAD51D mutations 
increase the risk of ovarian cancer, but not of breast, prostate, or colorectal cancer. 
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Table 7. Frequencies of the protein-truncating RAD51D c.576+1G>A mutation in different
patient groups.
Total wt (%) mut (%) p-value OR (95% CI)
Helsinki series
Population controls 1287 1286 (99.9%) 1 (0.1%)
Familial BC 819 818 (99.9%) 1 (0.1%) 1 1.57 (0.10-25.2)
Familial BC+OC 168 165 (98.2%) 3 (1.8%) a 0.006 23.4 (2.42-226)
≥3 affected 105 102 (97.1%) 3 (2.9%) 0.002 37.8 (3.90-367)
2 affected 63 63 (100%) 0 (0.0%) 1
Unselected BC 849 848 (99.9%) 1 (0.1%) a 1 1.52 (0.09-24.3)
Familial OC 8 8 (100%) 0 (0.0%) 1
Unselected OC 541 538 (99.4%) 3 (0.6%) a 0.080 7.17 (0.74-69.1)
Any OC b 707 702 (99.3%) 5 (0.7%) 0.024 9.16 (1.07-78.6)
Tampere series
Population controls 815 815 (100%) 0 (0.0%)
Unselected BC 691 690 (99.9%) 1 (0.1%) 0.459
Prostate cancer 1094 1094 (100%) 0 (0.0%) 1
Colorectal cancer 980 980 (100%) 0 (0.0%) 1
a The mutation-positive unselected BC patient and one of the mutation-positive 
unselected OC patients also belong to the familial BC+OC cohort; b Any OC 
includes patients with personal or family history of OC; BC = breast cancer, OC = 
ovarian cancer, wt = wild type, mut = carrier of the c.576+1G>A mutation. 
5.2.2 RAD51C c.790G>A MISSENSE VARIANT (I)
Given the suggestive association of the RAD51C c.790G>A missense variant with 
an increased risk among breast-ovarian cancer families in the study by Meindl et 
al. 139, we further genotyped the variant in unselected and familial breast and 
ovarian cancer patients and population controls from the Helsinki series. After 
combining the initial screening and the additional genotyped patients, the 
c.790G>A variant was detected in altogether seven breast and four ovarian 
cancer cases as well as in three controls (Table 8). The frequency of the variant 
did not significantly differ from controls in any of the patient subgroups (p > 




Table 8. Frequencies of the RAD51C c.790G>A missense variant in different patient
groups.
Total wt (%) mut (%) p-value OR (95% CI)
Population controls 1279 1276 (99.8%) 3 (0.2%)
Familial BC 803 800 (99.6%) 3 (0.4%) 0.682 1.60 (0.32-7.92)
≥3 affected 340 339 (99.7%) 1 (0.3%) 1 1.25 (0.13-12.1)
2 affected 463 461 (99.6%) 2 (0.4%) 0.613 1.85 (0.31-11.1)
Familial BC+OC 158 157 (99.4%) 1 (0.6%) 0.373 2.71 (0.23-26.2)
≥3 affected 96 96 (100%) 0 (0.0%) 1
2 affected 62 61 (98.4%) 1 (1.6%) 0.173 6.97 (0.71-68.0)
Unselected BC 833 829 (99.5%) 4 (0.5%) 0.444 2.05 (0.46-9.19)
Familial OC 8 8 (100%) 0 (0.0%) 1
Unselected OC 409 405 (99.0%) 4 (1.0%) 0.063 4.20 (0.94-18.8)
Any OC a 575 570 (99.1%) 5 (0.9%) 0.117 3.73 (0.89-15.7)
a Any OC includes patients with personal or family history of OC; BC = breast 
cancer, OC = ovarian cancer, wt = wild type, mut = carrier of the c.790>A variant. 
 
5.3 EFFECTS OF THE RAD51C AND RAD51D SPLICING
MUTATIONS (I, II)
We evaluated the effect of the RAD51C c.837+1G>A mutation on splicing in RNA 
samples of two carriers. Amplification of the cDNA with primers specific for 
RAD51C exons 3 and 8 produced three different-sized bands for the heterozygous 
mutation carriers and one band for a mutation-negative control sample on 
agarose gel (Study I: Figure 2). Sequencing of the PCR products revealed in the 
mutation-positive samples one mutant transcript lacking exons 4 and 5 and 
another mutant transcript lacking exon 5. The deletion of exons 4 and 5 disrupts 
the reading frame and leads to a premature stop-codon (p.Glu191GlyfsX12), 
whereas the deletion of exon 5 alone does not affect the reading frame 
(p.Val236_Ala279del). In the control sample, only the normal wild type transcript 
was present. 
The online tools Human Splicing Finder and MaxEntScan predicted that the 
RAD51D c.576+1G>A mutation disrupts the 5’donor splice site of exon 6, which 
may lead to a skipping over of adjacent exon(s), the inclusion of intron(s), or the 
use of cryptic splice sites, and ultimately to a truncated protein. 
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5.4 RAD51C AND RAD51D FAMILIES AND HAPLOTYPE
ANALYSIS (I, II)
Additional DNA samples from relatives were available for genotyping from three 
RAD51C and three RAD51D families in the Helsinki series. All the tested patients 
with invasive breast or ovarian cancer were mutation carriers.  
In the RAD51C c.837+1G>A breast-ovarian cancer family (Family 1), the 
mutation was observed in the breast cancer index patient and in her mother 
affected with breast cancer, while the healthy sister and daughter were non-
carriers (Figure 2A). Several other cancer types were observed in the family, such 
as ovarian, colorectal, uterine, brain, and prostate cancer, but no samples were 
available for genotyping. The c.837+1G>A was also observed in an ovarian cancer 
index patient whose mother was affected with ovarian cancer, but the DNA 
sample was only available from the index patient (Family 2).  
Segregation of the RAD51C c.93delG mutation was studied in one breast-
ovarian cancer family and in one ovarian cancer family. In the breast-ovarian 
cancer family (Family 3), all the studied relatives were carriers. These included 
one breast cancer and one breast-ovarian cancer patient, two relatives with skin 
cancer, two healthy males, and the breast cancer index patient herself. In the 
ovarian cancer family (Family 4), the healthy son of the index patient as well as 
the sister and her daughter were mutation carriers.  
The RAD51D c.576+1G>A mutation was observed in one breast cancer family 
(Family 5) where the index patient, her grandmother, and grandmother’s sister 
were affected with breast cancer, but the DNA sample was only available from 
the index patient (Figure 2B). The c.576+1G>A positive unselected ovarian 
cancer patient, who also belonged to the familial cohort, had a mutation-positive 
mother who was affected with ovarian cancer (Family 6). The index patient’s 
healthy son and daughter were also mutation carries, whereas no sample was 
available from the maternal aunt, who was affected with breast and gallbladder 
cancers. For the unselected breast cancer patient with the RAD51D mutation, 
samples were available from four healthy sisters, of whom two were non-carriers 
and two carried the mutation while no samples were available from relatives 
affected with breast or ovarian cancer (Family 7). In the third c.576+1G>A 
positive breast-ovarian cancer family, the index patient, her breast-cancer-
affected mother and healthy son and daughter carried the mutation (Family 8). 
The index patient’s sister, who had in situ breast cancer, did not carry the 
mutation, whereas no samples were available from the ovarian cancer patients. 
To investigate whether the identified RAD51C and RAD51D mutations 
represent founder mutations in the Finnish population, seven and eight SNPs 
within and adjacent to the RAD51C and RAD51D genes, respectively, were 
screened in family members from the mutation carrier families. Carriers of each 
mutation were found to share a common haplotype, which indicates a common 




Figure 2 Pedigrees of the RAD51C and RAD51D mutation carrier families. A, RAD51C
c.837+1G>A and c.93delG families. B, RAD51D c.576+1G>A families. The mutation status is
denoted above and the type of cancer below each individual with the age at onset in
parentheses. *Same individual. Mut = mutation-positive, wt = wild type, BC = breast cancer,
BM = bone barrow cancer, Cx = cervical cancer, Ut = uterine cancer, CRC= colorectal cancer,
OC = ovarian cancer, Pr = prostate cancer, Mel = melanoma, Pa = pancreatic cancer, Ki =
kidney cancer, Li = liver cancer, Ga = gallbladder cancer.
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5.5 CLINICAL CHARACTERISTICS OF RAD51C AND
RAD51D MUTATION CARRIERS (I, II)
The clinical and pathological characteristics of the mutation carriers from the 
Helsinki series are presented in Table 9. More information has been obtained for 
the RAD51D mutation carriers since the publication of the article. The mean age 
at first breast cancer diagnosis was 60.1 years among the five RAD51C mutation 
carriers and 55.5 among mutation-negative patients (p = 0.403), while the mean 
age at ovarian cancer diagnosis was 57.7 years for the seven carriers and 54.8 for 
the non-carries (p = 0.589). Among the four RAD51D mutation carriers, the mean 
age at first breast cancer diagnosis was 48.1 years, compared to 55.5 years 
among the non-carriers (p = 0.234). The mean age at ovarian cancer diagnosis 
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was 59.1 years for the four carriers and 54.9 years for the non-carriers (p = 
0.525).  
 
Table 9. Clinical and histopathological characteristics of the RAD51C and RAD51D
mutation carriers and tumors.
Cancer LOH dg-age T N M Grade Stage Tumorhistology ER  PR  HER2
RAD51C c.837+1G>A
Breast no 61.9 1 0 0 NA 1 Ductal NA NA NA
Breast yes 45.0 2 0 0 3 2A Ductal neg neg neg
Ovary yes 53 NA NA 1  3 3C Serous NA NA NA
Ovary yes 68 NA 1 1 2 3C Serous NA NA NA
Ovary NA 50 NA 0 0 2 1A Endometrioid NA NA NA
RAD51C c.93delG
Breast yes 54.7 1 0 0 3 1 Ductal neg neg pos
Breast NA 63.1 1 0 0 3 NA Lobular NA NA NA
Breast a NA 76 1 0 0 2 1 Lobular pos neg neg
Ovary a yes 59 NA NA 1 NA 1C Serous NA NA NA
Ovary yes 60 NA 0 1 1 3C Serous NA NA NA
Ovary yes 60 NA 1 1 3 3C Serous NA NA NA
Ovary yes 54 NA 1 1 3 4 Serous NA NA NA
RAD51D c.576+1G>A
Breast NA 30.8 1 0 0 3 1 Ductal neg neg neg
Breast no 53.8 2 1 0 2 2B Ductal pos pos neg
Breast NA 61.3 NA NA NA  3 NA Ductal NA NA neg
Breast NA 46.5 1 0 0 1 1 Ductal NA NA NA
Ovary yes 67 NA NA 1  3 NA Serous NA NA NA
Ovary yes 79 NA NA 1 NA NA NA NA NA NA
Ovary yes 53.6 NA NA NA  3 NA Serous NA NA NA
Ovary NA 37 NA NA NA NA NA Serous NA NA NA
a These tumors are from the same individual; dg-age = age at diagnosis, neg = 
negative, pos = positive, NA = not applicable. 
 
Three of the RAD51C breast tumors were of ductal histology and two were 
lobular. All four of the RAD51D breast tumors were ductal. The ovarian tumors 
were serous except for one endometrioid tumor from RAD51C c.837+1G>A 
carrier. The RAD51C breast tumors were of high grade, while the grade for 
RAD51D breast tumors varied; the ovarian tumors were mainly of high grade. 
Results 
52 
Information on hormone receptor and HER2 status was sparse; one RAD51C 
c.837+1G>A and one RAD51D c.576+1G>A breast tumor was triple-negative. LOH 
analysis revealed reduction of the wild-type allele for all studied ovarian tumors, 
whereas the one studied RAD51D breast tumor and one out of three RAD51C 
breast tumors did not show LOH. 
5.6 GENE-PANEL SEQUENCING (IV)
5.6.1 MUTATIONS IDENTIFIED IN GENE-PANEL SEQUENCING
In the gene-panel testing, 12 different pathogenic mutations were identified in 
18 out of 95 patients (19%) (Tables 10 and 11). Protein-truncating BRCA1 
mutations were detected in five patients (5.3%) and BRCA2 mutations in three 
patients (3.2%). The CHEK2 c.1100delC mutation was detected in seven patients 
(7.4%). Two of the c.1100delC-positive patients were compound heterozygotes 
and also carried the CHEK2 splicing mutation c.444+1G>A. Thus, altogether 20 
mutations were detected. All six of the female c.1100delC carriers were 
diagnosed with breast cancer at an early age (range 22–39 years), while the 
seventh carrier was a male patient affected with breast and thyroid cancer. Two 
of the BRCA1-positive patients and one CHEK2-positive patient also carried the 
CHEK2 low-penetrance missense variant c.470T>C p.Ile157Thr (I157T). In total, 
the c.470T>C variant was detected in six patients. Of the 20 patients from families 
previously negative for BRCA1/2 mutations, one harbored the CHEK2 c.1100delC 
and c.444+1G>A mutations and one had a BRCA1 nonsense mutation that was not 
covered by the previous founder mutation screening. 
One pathogenic missense mutation was observed in each of the PTEN and 
TP53 genes. The identified PTEN and TP53 missenses are classified as pathogenic 
mutations in the ClinVar (RCV000169787.2 and RCV000129010.2) and HGMD 
databases and neither is observed in the ExAC database. The PTEN mutation was 
observed in a woman diagnosed with breast cancer at the age of 39. Her mother 
had been diagnosed with breast cancer at the age of 63 and maternal aunt with 
synovial sarcoma at the age of 43 and breast cancer at the age of 45. More careful 
medical inspection after the genetic test result revealed a fibroma, goiter and 
several trichilemmomas, but a normal head circumference. The TP53 mutation 
was observed in a woman diagnosed with bifocal breast cancer at the age of 29. 
Her maternal grandfather’s sister had breast cancer at an old age and maternal 
aunt colon cancer at the age of 55. In RAD51C, the splicing mutation c.837+1G>A 
identified in Study I was observed in a woman diagnosed with ovarian and 
uterine cancers at the age of 40. No deleterious mutations in RAD51D, STK11, or 





Table 10. Pathogenic mutations observed in the gene-panel testing and clinical and
histopathological features of the carrier tumors.
Mutation Cancer (dg-age) Histology a Grade ER PR HER2
BRCA1 (transcript NM_007294.3)
c.3626delT BC (34) ductal NA neg NA NA
c.3626delT b BC bilat (43+48) ductal 3 neg neg neg
c.4656C>A p.Tyr1552Ter b BC (52), OC (58) ductal 1 pos pos NA
c.5278-1G>C BC (31) ductal NA neg neg neg
c.4186-1787_4357+4122dup
(ex13 duplication c)
BC bilat (54+54) ductal 3 neg neg neg
BRCA2 (transcript NM_000059.3)
c.1286T>G p.Leu429Ter BC (38) ductal 3 neg neg pos
c.7480C>T p.Arg2494Ter BC (60), OC (54) ductal NA pos neg neg
c.8314G>T p.Glu2772Ter BC (26) ductal 2-3 pos pos pos
CHEK2 (transcript NM_007194.3)
c.1100delC b BC bifocal (22) ductal 3 pos pos pos
c.1100delC BC (34) ductal 3 pos neg neg
c.1100delC BC (25) ductal 2 pos pos pos
c.1100delC BC (26) ductal 2 pos pos pos
c.1100delC BC (30) ductal 3 pos neg pos
c.1100delC; c.444+1G>A BC bilat (39+69) ductal 2 NA NA NA
c.1100delC; c.444+1G>A MBC (46), thyroid (28) ductal 2 pos pos neg
PTEN (transcript NM_000314.6)
c.70G>T p.Asp24Tyr BC (39) duct et
lobular
3 pos pos neg
TP53 (transcript NM_000546.5)







c.837+1G>A OC (40), uterine (40) serous 3 pos NA NA
a Histology, grade, and ER, PR, and HER2 status are denoted for the first breast 
tumor; for the patient without breast cancer, the information is given for the 
ovarian tumor. b Patient also carries the CHEK2 c.470T>C p.Ile157Thr low-
penetrance variant; c exon numbering based on U14680.1 transcript; dg-age = 
age at diagnosis, BC = breast cancer, NA = not applicable, neg = negative, bilat = 





Table 11. Number of mutation-positive patients in different ascertainment groups.
Ascertainment criteria Mutation carriers Mutated genes (number of mutation carriers)
BC family ≥3 affected 6 of 35 (17%) BRCA1 (2), BRCA2 (1), CHEK2 (2), PTEN (1)
BC only (≥3 affected) 4 of 20 (20%) BRCA1 (1), CHEK2 (2), PTEN (1)
BC+OC (≥3 affected) 2 of 15 (13%) BRCA1 (1), BRCA2 (1)
BC family 2 affected 5 of 23 (22%) BRCA1 (1), BRCA2 (1), CHEK2 (2), RAD51C (1)
BC only (2 affected) 3 of 14 (21%) BRCA2 (1), CHEK2 (2)
BC+OC (2 affected) 2 of 9 (22%) BRCA1 (1), RAD51C (1)
early-onset BC 4 of 18 (22%) BRCA2 (1), CHEK2 (2), TP53 (1)
TNBC 2 of 10 (20%) BRCA1 (2)
MBC 1 of 5 (20%) CHEK2 (1)
other a 0 of 4 (0%) -
All 18 of 95 (19%) BRCA1 (5), BRCA2 (3), CHEK2 (7), PTEN (1),TP53 (1) , RAD51C (1)
a Includes three breast-ovarian cancer patients and one breast-colorectal cancer 
patient with a family history of other cancers; BC = breast cancer, OC = ovarian 
cancer, MBC = male breast cancer. 
 
Among the 20 identified mutations was one CNV, which was a known BRCA1 exon 
13 duplication accounting for 20% of the all the observed mutations in BRCA1 
and 5% of all the observed pathogenic mutations in any gene. In addition to the 
pathogenic mutations detected in 18 patients, a novel heterozygous RAD51C 
duplication was identified in the CNV analysis. Together, the BRCA1 and RAD51C 
duplications accounted for 9.5% of all the observed pathogenic or potentially 
pathogenic mutations. The RAD51C duplication was identified in a woman 
diagnosed with breast cancer at the age of 40 and basal cell carcinoma at the age 
of 45. She had previously tested negative for BRCA1/2 mutations. According to 
the CNV analysis, the duplication starts upstream of the RAD51C gene around 
chromosomal position chr17:56,738,600 and ends in the RAD51C intron 7 
around position chr17: 56,802,672. With Sanger sequencing the mutation was 
characterized as a 64 179 base-pair (bp) long duplication (chr17:56,738,493-
56,802,671), starting 31 512 bp upstream of the RAD51C start codon and 
extending to RAD51C intron 7 with a 10 bp insertion CTTTTGTGAG between the 
two copies (c.-31512_965+1210dup{insCTTTTGTGAG}). Thus, there is an extra 
copy of RAD51C exons 1–7 located 31 kb upstream of the full-length gene (Study 
IV: Figure 1). 
5.6.2 GENOTYPING OF THE RAD51C DUPLICATION
The duplication carrier had three sisters affected with breast cancer. Ovarian 
cancer as well as various other cancer types, such as Hodgkin lymphoma, 
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colorectal cancer, and prostate cancer, were observed among distant relatives. 
Two of the breast-cancer-affected sisters were duplication carriers, whereas no 
duplications were observed in the three tested healthy women (Figure 3).  
 
Figure 3 Pedigree of the RAD51C duplication family. The mutation status is denoted above
and the type of cancer below each individual with the age at onset in parentheses. Dup =
duplication carrier, wt = non-carrier, SC = spinal cord, Pr = prostate cancer, HL = Hodgkin’s
lymphoma, CRC = colorectal cancer, Leu = leukemia, Te = testicular cancer, OC = ovarian
cancer, BC = breast cancer, BCC = basal cell carcinoma, dup = duplication.
 
Genotyping of the duplication in familial and unselected breast and ovarian 
cancer patients and population controls revealed seven duplication carriers 
among cases and none among controls. Three carriers were identified among 
unselected breast cancer patients, with one of them also affected with ovarian 
cancer, and two were identified among unselected ovarian cancer patients. No 
additional carriers were identified among breast–ovarian cancer families, 
whereas two duplications were observed among breast-cancer-only families. 
After combining the 46 familial BRCA1/2-negative breast or ovarian cancer 
patients from the gene-panel testing with the genotyped patients, eight 
duplication carriers were identified and half of them had a personal or family 
history of ovarian cancer. All the duplication carriers were negative for the 
RAD51C c.93delG and c.837+1G>A mutations. The frequency of the duplication 
was significantly higher among ovarian cancer cases (0.5%) than among 
population controls (0.0%) (p = 0.032) (Table 12). 
Two of the breast tumors from duplication carriers were of ductal histology, 
two were lobular and two were tubular. Two of the ovarian tumors were of 




Table 12. Frequencies of the RAD51C duplication in different patient groups.
a One of the duplication-positive unselected breast cancer patients was affected 
by both breast and ovarian cancer and is also included in the All OC patient group; 
b Unselected and familial OC patients as well as BC+OC patients from the 
unselected and familial BC cohorts are included in the All OC patient group; c Any 
OC includes all patients with personal or family history of OC; wt = wild type, dup 
= duplication carrier, BC = breast cancer, OC = ovarian cancer. 
5.6.3 RAD51C EXPRESSION
The RAD51C RNA expression was measured in LCLs of three duplication carriers 
and two non-carriers in order to study whether the duplication is transcribed 
into mRNA and whether it affects the expression level of RAD51C. When the 
RAD51C expression was measured with a probe binding to the boundary of 
RAD51C exons 1-2 and ACTB was used as an endogenous control, two of the 
carriers showed significantly increased RAD51C expression compared to the 
non-carrier control sample (RQ = 1.52, p = 0.020 and RQ = 1.68, p = 0.013) with 
the third carrier showing a 1.23-fold increase (p = 0.141) (Table 13; Study IV: 
Figure 2). On average, the three carriers showed 1.48-fold increased RAD51C 
expression (p = 0.074 compared to the two non-carries). When the expression 
was measured with the RAD51C exons 8-9 probe, residing outside of the 
duplicated area, the expression levels were comparable in the carriers and non-
carriers. Finally, when the expression was measured with the RAD51C exons 1-2 
probe and the exons 8-9 probe was used as a control, the duplication carriers 
showed 1.21 to 1.66-fold increased expression, one of them with significantly 
increased expression compared to the control (p = 0.006). On average, the three 
carriers showed 1.42-fold increased expression of the RAD51C exons 1-2 (p = 
0.084 compared to the two non-carriers). The observed fold-change suggests 
that a stable aberrant mRNA may be produced and is concordant with the 
heterozygous carriers having three copies of RAD51C exons 1-7 and two copies 
of exons 8-9 in their genomes. 
Patient group Total Wt (%) Dup (%) p-value
Population controls 1273 1273 (100.0%) 0 (0.0%)
All BC 2533 2527 (99.8%) 6 (0.2%) 0.188
Unselected BC 1729 1726 (99.8%) 3 (0.2%) a 0.267
Familial BC 973 971 (99.8%) 2 (0.2%) 0.188
Familial BC+OC 214 213 (99.5%) 1 (0.5%) 0.144
All OC b 590 587 (99.5%) 3 (0.5%) a 0.032
Unselected OC 553 551 (99.6%) 2 (0.4%) 0.092
Familial OC 8 8 (100.0%) 0 (0.0%) 1
Any OC c 782 778 (99.5%) 4 (0.5%) 0.021
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Table 13. Expression of RAD51C ex1-2 and ex8-9 normalized to ACTB and expression of
RAD51C ex1-2 normalized to RAD51c ex8-9 in three duplication carriers (Dup 1-3) and one
non-carrier (wt) compared to a healthy non-carrier (Control).
RAD51C ex1-2 vs ACTB RAD51C ex8-9 vs ACTB RAD51C ex1-2 vs ex8-9
Samples RQ SEM p-value RQ SEM p-value RQ SEM p-value
Dup 1 1.23 0.09 0.141 0.89 0.16 0.514 1.39 0.16 0.068
Dup 2 1.68 0.15 0.013 1.01 0.15 0.941 1.66 0.10 0.006
Dup 3 1.52 0.11 0.020 1.26 0.17 0.245 1.21 0.10 0.172
wt 1.10 0.16 0.564 1.03 0.16 0.865 1.07 0.07 0.589
Control 1 0.15 1 0.20 1 0.14
RQ = relative quantification; SEM = standard error of the mean; dup = duplication 
carrier; wt = wild type 
 
 
The mRNA produced from the duplication was further characterized in RNA 
samples of three duplication carrier and two wild-type control LCLs. The 
duplication spans the first seven exons that encode amino acids 1–322 in the 
wild-type RAD51C protein. If the translation continues into intron 7, a new stop 
codon would be encountered after 18 amino acids, p.(Phe323SerfsTer18). 
Consistent with this, PCR using primers in exons 4 and 7 produced an expected 
300 bp long product in both the duplication carriers and controls, but primers at 
the exon 4-5 junction and in intron 7 produced a novel 663 bp long product 




6.1 GERMLINE MUTATIONS IN RAD51C AND RAD51D
INCREASE OVARIAN CANCER RISK
Two pathogenic, recurrent mutations in the RAD51C gene and one in the RAD51D 
gene were identified among Finnish breast and ovarian cancer patients in this 
study, but no RAD54L mutations were observed. Although the sample set was 
small, the results suggest that the RAD54L gene does not substantially contribute 
to breast or ovarian cancer predisposition in the Finnish population. To date, no 
conflicting reports have been published in the literature. In a targeted sequencing 
study including 12 DNA repair genes, Dicks et al. detected only five RAD54L 
germline mutations among over 4 500 ovarian cancer patients with a mutation 
frequency similar to that of healthy controls 236. Taken together, it is unlikely that 
RAD54L plays a significant role in breast or ovarian cancer predisposition, 
although rare mutations or small risk effects cannot be ruled out. 
The RAD51C mutations were detected only in patients with personal or family 
history of ovarian cancer, but not among breast-cancer-only families or 
unselected breast cancer patients in the Helsinki series. This is consistent with 
the initial report by Meindl et al. where RAD51C was proposed as a breast and 
ovarian cancer susceptibility gene 139. Our results, however, indicate that RAD51C 
mutations primarily predispose to ovarian cancer, but are not associated with 
breast cancer in the absence of ovarian cancer family history, suggesting RAD51C 
as the first moderate-penetrance ovarian cancer susceptibility gene. While most 
of the early papers published before Study I did not identify pathogenic 
mutations among breast or ovarian cancer patients 147-150, several studies 
published since have reported rare RAD51C mutations, mainly among breast-
ovarian or ovarian-cancer-only families or unselected ovarian cancer patients 121, 
237-248. As the mutations are very rare, only a few studies have been able to 
estimate the associated cancer risks, whereas the recurrent founder mutations 
observed in this study allowed us to perform case-control analyses. The OR of 6.3 
observed here among unselected ovarian cancer patients suggests a moderate to 
high risk of ovarian cancer for the mutation carriers. Loveday et al. and Song et 
al. later confirmed the association with ovarian cancer, with estimated relative 
risks between 5.2 and 5.9 (Table 14), in line with our results 121, 247. For the serous 
subtype, Song et al. estimated a higher OR of 7.4 (95% CI = 1.6-35) 247.  
RAD51D was originally established as an ovarian cancer susceptibility gene 
by Loveday et al., with pathogenic mutations conferring a 6.3-fold relative risk of 
ovarian cancer, but no significant increase in breast cancer risk 122. Consistently, 
we observed an elevated frequency of the RAD51D mutation among breast-
ovarian cancer families and among patients with personal or family history of 
ovarian cancer, while the mutation frequency among unselected breast cancer 
patients was not significantly higher than among population controls. Since then, 
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rare RAD51D mutations have been observed in several follow-up studies among 
ovarian cancer patients and breast-ovarian cancer families, but not among 
breast-cancer-only families 246, 247, 249-253. As with RAD51C, only a few studies have 
estimated the cancer risks associated with RAD51D mutations. The OR of 7.2 
observed in this study among unselected ovarian cancer patients, although not 
reaching statistical significance, suggests an increased risk of ovarian cancer and 
is in line with the risk estimated by Loveday et al. 122. Similar results were 
obtained by Song et al., albeit with a higher OR of 12 both for all ovarian cancer 
subtypes (Table 14) and for the serous subtype (OR = 12, 95% CI = 1.5-97) 247. 
To date, the study by Song et al. remains the largest population-based case-
control study on the RAD51C and RAD51D genes, as it includes 3 429 ovarian 
cancer cases and 2 772 controls 247. Both for the RAD51C and for the RAD51D 
mutation carriers, they estimated an average cumulative ovarian cancer risk of 
1.3% by age 50, whereas the cumulative risk by age 70 was 5.2% for RAD51C 
carriers and 12% for RAD51D carriers.  
 
Table 14. Reported ovarian cancer risk estimates for RAD51C and RAD51D mutation
carriers.
Study ref Cases Controls RAD51C relative risk RAD51D relative risk
Loveday et al.
2011 122
911 1 060 NA 6.3 (95% CI = 2.9-14,
p = 4.8 × 10-6)
Loveday et al.
2012 121
1 404 1 156 5.9 (95% CI = 2.9−12,




3 429 2 772 5.2 (95% CI = 1.1-24,
p = 0.035)






16 (95% CI = 1.9-128,
p = 0.002)
9 (95% CI = 1.9-43,
p = 0.002)
36 276 b 3.4 (95% CI = 1.5-7.9,
p = 0.005)




7 768 ~25 000 c 5.1 (95% CI = 3.7-6.9, p
= 1.1 × 10−16)
6.3 (95% CI = 3.2-11,
p = 4.4 × 10−6)
a ESP European American reference controls; b ExAC reference controls; c ExAC 
non-Finnish European non-TCGA reference controls; ref = reference 
 
The association of RAD51C and RAD51D germline mutations with ovarian cancer 
has been further confirmed in two large gene-panel studies where the mutation 
frequencies in ovarian cancer patients were compared to the frequencies in 
publicly available reference controls 254, 255. Norquist et al. analyzed 1 915 
unselected ovarian cancer patients compared to controls from the NHLBI GO 
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Exome Sequencing Project (ESP) and from ExAC 254. The ORs ranged between 3.4 
and 16 for RAD51C mutations and 9-11 for RAD51D mutations (Table 14). 
Lilyquist et al. analyzed 10 203 ovarian cancer cases referred for clinical testing 
and estimated the risks based on 7 768 patients of European ancestry compared 
to ExAC non-TCGA controls 255. RAD51C mutations were associated with a 5.1-
fold and RAD51D mutations with a 6.3-fold increased risk of ovarian cancer. 
Although the large size of the latter study allows more precise risk estimates, the 
study population was enriched for patients with a positive family history, which 
can lead to an overestimation of risk. However, the risk estimates are similar to 
those obtained by us, Loveday et al., and Song et al. 121, 122, 247. 
 
6.2 RAD51C AND RAD51D MUTATIONS IN BREAST
CANCER PREDISPOSITION
While our results together with the data from other studies strongly indicate that 
pathogenic mutations in RAD51C and RAD51D increase the risk of ovarian cancer, 
the association with breast cancer risk has been more controversial. The absence 
of RAD51C mutations among breast-cancer-only families and unselected breast 
cancer patients from Helsinki indicates that RAD51C mutations are not 
associated with an increased risk of breast cancer. Concordantly, while two 
RAD51C mutations were detected in the Tampere unselected breast cancer 
series, the frequency did not differ from that among controls. The RAD51D 
mutation was detected once among breast-cancer-only families and once in the 
Helsinki and Tampere unselected breast cancer series; however, these 
frequencies were similar to those of the controls. The presence of multiple breast 
cancer cases in some of the mutation carrier families suggests that other 
susceptibility alleles may be segregating and confer an increased risk of breast 
cancer, or potentially modify the effect of the RAD51C or RAD51D mutations. 
Consistent with our results, Loveday et al. did not observe a significant 
association with breast cancer for either gene in modified segregation analyses 
121, 122. However, while there was no evidence of association for RAD51C with 
breast cancer (RR = 0.91, 95% CI = 0.45−1.86, p = 0.8), the confidence intervals 
for RAD51D were wider (RR = 1.32, 95% CI = 0.59–2.96, p = 0.50).  
Recently, the breast cancer association of RAD51C and RAD51D mutations 
have been studied in large gene-panel studies. Couch et al. observed six RAD51C 
and seven RAD51D mutations among 1 824 unselected TNBC patients 256. 
Interestingly, none of the RAD51C mutation carriers and only one RAD51D carrier 
had a family history of ovarian cancer. Buys et al. identified 53 RAD51C and 19 
RAD51D mutations among 35 409 breast cancer patients who underwent clinical 
genetic testing 257. The RAD51C mutations were significantly enriched in women 
with TNBC compared to women with other breast cancer subtypes (0.4% versus 
0.1%; p < 0.001). In contrast, only one of the five RAD51C breast tumors and one 
of the four RAD51D tumors in our study were triple-negative. Moreover, as 
 
61 
neither of these studies performed case-control comparisons, no conclusions 
about the associated breast cancer risks can be drawn. In the largest study thus 
far, Couch et al. detected RAD51C mutations in 0.09% and RAD51D mutations in 
0.07% of 38 326 breast cancer patients undergoing clinical genetic testing 258. 
Compared to ExAC non-Finnish European controls, the RAD51C mutations were 
not associated with an increased risk of breast cancer (OR = 0.78, 95% CI = 0.47-
1.37, p = 0.43), but rather were associated with a family history of ovarian cancer 
(OR = 2.89, 95% CI = 1.26-6.45, p = 0.01). Pathogenic variants in RAD51D, on the 
other hand, were associated with a moderate risk of breast cancer (OR = 3.07, 
95% CI = 1.21-7.88, p = 0.01). Even though the use of non-matched reference 
controls is not ideal, the very large size of this study allowed estimation of the 
breast cancer risk associated with these rare mutations. Taken together, our 
results together with other studies indicate that RAD51C mutations do not 
increase breast cancer risk, although the role of RAD51C in specific breast cancer 
subtypes, such as TNBC, cannot be fully excluded. RAD51D mutations, however, 
may be associated with a moderate risk of breast cancer, but further research is 
required to confirm and better define the associated risk. 
6.3 RAD51C AND RAD51D MUTATION CARRIER
FAMILIES AND OVARIAN TUMORS
The RAD51C mutations were significantly more frequent among the familial than 
unselected ovarian cancer patients, but no RAD51D mutations were detected 
among ovarian-cancer-only families.  However, the sample set of ovarian-cancer-
only families in this study was very small. Although not statistically significant, 
Song et al. observed that ovarian cancer patients with a mutation in any of the 
RAD51B, RAD51C, or RAD51D genes were more likely to have ovarian cancer 
family history (24%) than patients without mutations (14%) 247. In line with our 
results, a higher proportion of patients with RAD51C mutations had a positive 
family history (36%, p = 0.021), whereas only 10% of patients with RAD51D 
mutations had a family history of ovarian cancer. Consistently, RAD51C 
mutations were also associated with ovarian cancer family history in the gene-
panel study of breast cancer patients by Couch et al. 258. 
As is typical for moderate-penetrance susceptibility genes 39, the RAD51C and 
RAD51D mutations displayed incomplete segregation with the disease. 
Concordantly with Meindl et al. and Loveday et al. 122, 139, all the tested patients 
with invasive breast or ovarian cancer in the RAD51C and RAD51D families were 
mutation carriers, but mutations were also detected in healthy women. In line 
with Meindl et al. 139, we observed loss or reduction of the wild type allele in all 
the studied RAD51C and RAD51D ovarian tumors. In contrast, Loveday et al. 
observed LOH in one of the two available RAD51D ovarian tumors, while the 
other tumor had lost the mutant allele which is also typical for moderate-
penetrance genes 122. 
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The mutation carriers were diagnosed with ovarian cancer between 37 and 
79 years of age with a slightly younger average age for RAD51C carriers (57.7) 
than for RAD51D carriers (59.1). For both genes, the average age at diagnosis was 
higher for mutation carriers than for non-carriers, but lower than the 62 years 
previously reported for the general population in Finland 259. Slightly higher 
average age at ovarian cancer onset for RAD51C carriers was observed by Meindl 
et al. and Gevensleben et al.: 60 and 61.3, respectively 139, 260. In line with our 
results, Song et al. and Lilyquist et al. reported an earlier ovarian cancer onset for 
RAD51C carriers than for RAD51D carriers 247, 255. Song et al. observed that 64% 
of RAD51C and 58% of RAD51D mutation carriers were diagnosed with ovarian 
cancer at an age younger than 60 compared to 52% of non-carriers diagnosed at 
this age 247. Four of the RAD51C carriers (29%) were diagnosed at the age of 40-
49, whereas only one RAD51D carrier (8.3%) was diagnosed at this age. Lilyquist 
et al. observed a higher prevalence of RAD51D mutations among patients 
diagnosed at age 60 or older than among patients younger than that (p = 0.03), 
whereas for RAD51C mutations there was no difference between the age 
groups 255. In contrast, Norquist et al. reported a higher median age for RAD51C 
carriers (64) than for RAD51D carriers (54) or for patients with no mutations 
(62) 254. However, all these studies, including ours, are based on rather small 
numbers of mutation carriers and there is a wide range in the age of onset. 
The rarity of the mutations and the limited histopathological information 
makes it difficult to estimate whether RAD51C or RAD51D mutations are 
associated with a specific tumor phenotype. The ovarian cancers in RAD51C and 
RAD51D mutation carriers in this study were mainly of the most common serous 
subtype, in line with the initial reports by Meindl et al. and Loveday et al. 122, 139. 
Consistent observations have been made in several follow-up studies with the 
majority of the ovarian tumors in RAD51C and RAD51D mutation carriers being 
HGSCs 247, 254, 255, 260. Furthermore, Song et al. estimated that carriers of RAD51B, 
RAD51C, or RAD51D mutations are more likely than non-carriers to have a high-
grade serous tumor versus other histologic subtypes (p = 0.046) 247. 
Loveday et al. demonstrated that RAD51D deficient cells are sensitive to the 
PARP inhibitor olaparib 122 and later Min et al. showed that RAD51C-deficient 
cancer cells are also sensitive to olaparib 261. Moreover, Somyajit et al. discovered 
that RAD51C-deficient cells and cells with hypomorphic RAD51C mutations 
display increased activity of the error-prone repair mechanism NHEJ, and the 
toxicity of PARP inhibitors can be enhanced synergistically by stimulating NHEJ 
with a low dose of ionizing radiation in these cells 262. Thus, like patients with 
BRCA1 or BRCA2 mutations, ovarian cancer patients with RAD51C or RAD51D 
mutations could potentially be treated with PARP inhibitors. 
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6.4 RAD51C AND RAD51D IN PROSTATE AND
COLORECTAL CANCER PREDISPOSITION
Germline mutations in some breast and ovarian cancer susceptibility genes 
predispose to other cancer types as well, for example, BRCA2 mutations also 
increase the risk of prostate and pancreatic cancers 171, 175, 263. As diverse tumor 
types, such as uterine, prostate, pancreatic, and colorectal cancer, were present 
in the RAD51C and RAD51D mutation-positive families, we were prompted to 
study the role of the mutations in other common cancers. Various cancer types 
have been observed in mutation-positive families in other studies, as well 121, 122, 
139, 237, 239, 240, 242-244, 246, 248, 249, 264. The recurrent founder mutations identified here 
enabled a rapid and straightforward screening of extensive sets of prostate and 
colorectal cancer patients. 
The absence of the RAD51C and RAD51D founder mutations among the 
prostate and colorectal cancer patients suggests that the mutations do not 
predispose to these cancer types. Thus, it is unlikely that the RAD51C or RAD51D 
genes contribute significantly to prostate or colorectal cancer predisposition in 
the Finnish population, although rare susceptibility alleles cannot be excluded. 
Other studies on RAD51C and RAD51D in prostate or colorectal cancer are very 
scarce. In a gene-panel study of 692 men with metastatic prostate cancer, 
Pritchard et al. identified one RAD51C and three RAD51D mutations 176. The 
frequency of RAD51C mutations did not differ between patients and ExAC 
controls, whereas the frequency of RAD51D mutations was elevated, albeit with 
a nominal p-value of 0.02 that would not survive multiple-testing correction. 
Rivera et al. identified a pathogenic RAD51D missense mutation, which was a 
founder mutation in the French Canadian population and associated with 
increased risk of ovarian cancer, but was not observed among 154 colorectal 
cancer patients 253. In gene-panel studies, Yurgelun et al. identified one RAD51C 
and no RAD51D mutations among 1 260 patients with suspected Lynch 
syndrome, and Pearlman et al. identified no RAD51C or RAD51D mutations 
among 450 patients with early-onset colorectal cancer 265, 266. To fully establish 
the role of RAD51C and RAD51D mutations in prostate and colorectal cancer 
predisposition, further studies screening the whole coding regions of the genes 
in large sample-sets and in other populations are warranted.  
6.5 GENE-PANEL TESTING IDENTIFIES MUTATIONS IN
VARIOUS GENES
The gene-panel sequencing of 95 high-risk breast or ovarian cancer patients 
revealed clearly pathogenic mutations in 18 patients (19%) and a novel RAD51C 
duplication in a further patient (1.1%). The proportion of mutation-positive 
patients is somewhat higher than in the recent large gene-panel studies of breast 
cancer patients undergoing clinical genetic testing; Buys et al. reported 
pathogenic variants in 9.3% of 35 409 patients and Couch et al. in 10.2% of 
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41 611 patients 257, 258. Smaller studies, however, have reported pathogenic 
mutations in approximately 12–22% of breast or ovarian cancer patients, which 
is more consistent with our results 267-271. In our study, BRCA1 or BRCA2 
mutations were observed in 8.4% of the patients and mutations in other genes in 
10.5% of the patients. The most frequently mutated gene was CHEK2 with 7.4% 
of the patients carrying at least one mutation in the gene, and the CHEK2 
mutations comprising 45% of all the identified pathogenic mutations. This is not 
surprising as the CHEK2 c.1100delC has one of the highest population 
frequencies in Finland and has been observed in 5.5% of Finnish breast cancer 
families 168. Several other gene-panel studies of high-risk breast or ovarian 
cancer patients have detected mutations in genes other than BRCA1/2 in 
approximately 4–7% of patients, which is a smaller proportion than in our study 
245, 257, 258, 267, 269-273. Most of the difference is accounted for by the high prevalence 
of the CHEK2 c.1100delC mutation in our study and in the Finnish population. 
While CHEK2 was the most commonly mutated gene after BRCA1 and BRCA2 in 
the large gene-panel studies, Buys et al. and Couch et al. observed CHEK2 
mutations in only 1.1–1.7% of the patients 257, 258. The genes included in the 
panels as well as the eligibility criteria for the patients varies between different 
studies, which likely also contributes to the number of mutation-positive patients 
reported. 
The proportion of mutation-positive patients did not differ much between the 
patient groups ascertained on the basis of different criteria; mutations were 
detected in approximately 20% of the patients in most of the subgroups. The 
mutated genes, however, correlated with clinical and tumor characteristics. 
Among the ten patients ascertained based on the TNBC criteria, two BRCA1 
mutations were observed consistent with BRCA1 tumors being often triple-
negative 123-125. The only mutation-positive patient affected with ovarian cancer 
but not breast cancer carried the RAD51C splicing mutation, whereas BRCA1 and 
BRCA2 mutations were observed in patients affected with both breast and 
ovarian cancer. This is concordant with RAD51C mutations increasing the risk of 
ovarian cancer and not breast cancer, but BRCA1 and BRCA2 mutations 
increasing the risk of both of these cancers 70, 121. CHEK2 mutations were 
observed in six women, all diagnosed with breast cancer before the age 40, and 
in a man affected with breast and thyroid cancer. All of the tumors with 
information on hormone receptor status were ER-positive. Consistently, 
previous studies have indicated an increased risk of ER-positive breast cancer, 
male breast cancer, and thyroid cancer for CHEK2 mutation carriers and shown 
that the relative risk of breast cancer for CHEK2 c.1100delC carriers decreases 
with age 118, 144, 274. 
The PTEN and TP53 missense mutations detected in this study have been 
previously reported in PHTS and LFS families and the TP53 mutation has been 
shown to function as a dominant negative allele 275-277. In this study, however, the 
mutations were observed in patients who did not present the most typical 
features of PHTS or LFS. Interestingly, the PTEN mutation carrier had features of 
Li-Fraumeni-like syndrome with an early-onset breast cancer and a family 
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history of breast cancer and sarcoma although after the genetic test result, she 
was found to have a fibroma, goiter and trichilemmomas typical for PHTS. The 
TP53 mutation carrier did not fulfill the Chompret criteria for TP53 testing, but 
she was diagnosed with an early-onset HER2-positive breast cancer consistent 
with a previously suggested association between germline TP53 mutations and 
early-onset HER2-positive breast cancer 133, 278.  
Two of the mutation-positive patients (8.7%) had two different protein-
truncating mutations with both patients carrying the CHEK2 mutations 
c.1100delC and c.444+1G>A. In addition, three patients had a BRCA1 or CHEK2 
protein-truncating mutation and the CHEK2 low-penetrance missense variant 
c.470T>C (I157T). Individuals with two pathogenic mutations may be at a higher 
risk than individuals with a single mutation, and low-penetrance variants may 
modify the risk of high and moderate-penetrance mutations. Previous studies 
indicate a higher risk of breast cancer for CHEK2 compound heterozygotes and 
c.1100delC homozygotes than for CHEK2 heterozygotes, but an additional CHEK2 
mutation may not further increase the risk of a BRCA1-positive woman 279-281. 
The common low-risk SNPs, individually and especially in combination, have 
been shown to modify breast cancer risk in BRCA1/2 and CHEK2 mutation 
carriers 159-161. Thus, the identification of two different mutations has value for 
the counselling of the patient as well as in the testing and counselling of family 
members, when both mutations are segregating in the family. Other breast or 
ovarian cancer gene-panel studies have also observed individuals with multiple 
susceptibility alleles, with approximately 1–4% of the mutation-positive patients 
carrying more than one mutation 238, 254-256, 267. Gene panels have also uncovered 
pathogenic mutations in another susceptibility gene in patients who have 
previously tested negative for BRCA1/2 mutations 245, 272, 273. Lincoln et al. 
compared traditional BRCA1/2 testing with gene-panel testing and observed 
deleterious mutations in other susceptibility genes in 3.9% of BRCA1/2-negative 
patients 282. Moreover, additional deleterious mutations in other genes were 
observed in two BRCA1/2-positive patients as well as in two patients previously 
tested negative for the BRCA1/2 mutation segregating in the family. In our study, 
three of the patients who had undergone previous BRCA1/2 testing were now 
found to harbor either CHEK2 or BRCA1 mutations or the RAD51C duplication. 
Compared to BRCA1/2 testing, panel testing of BRCA1, BRCA2, RAD51C, RAD51D, 
BRIP1, and PALB2 mutations based on family history or clinical criteria has been 
shown to be more cost-effective in the UK and US populations 283. 
6.6 CNVS IDENTIFIED IN THE GENE-PANEL STUDY
Of note, two CNVs were detected among the patients tested on the gene panel: a 
known BRCA1 duplication and a novel RAD51C duplication, which together 
accounted for 9.5% of all the observed pathogenic or potentially pathogenic 
mutations. Approximately 7% of the mutations detected in other gene-panel 
studies have also been CNVs and have occurred most commonly in BRCA1 238, 254, 
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255, 267, 270. The high proportion of genomic changes here and in other studies 
underscores the importance of including a CNV detection method in cancer 
predisposition testing. 
The RAD51C duplication was further observed in 0.5% of ovarian cancer 
patients but was absent among population controls (p = 0.032), which suggests 
an increased risk of ovarian cancer for the carriers, consistent with the results of 
Study I on the RAD51C point mutations and with other published studies on 
RAD51C 121, 247, 254, 255. Concordantly, the duplication frequency was not 
significantly elevated in breast cancer patients compared to population controls.  
Previous studies have identified a recurrent RAD51C exon 5-9 deletion in 
breast or breast-ovarian cancer families 284, 285. In ExAC, a duplication covering 
RAD51C exons 1-7 has been observed in 12 of 3 301 Finnish samples 234. The 
Finnish samples on ExAC are from diverse population cohorts collected in 
different parts of the country. If the ExAC CNV represents the same duplication 
as described here, it may be possible that the duplication is more prevalent in 
some other parts of Finland. Due to the ancient Finnish population history, the 
allele frequencies differ between different geographical regions in Finland 169, 170. 
This is evident, for example, with BRCA1/2 founder mutations, which show 
geographical clustering in Finland 166. However, limitations of the ExAC CNV data 
should be noted as it is difficult to make accurate CNV calls from targeted short 
read sequencing data and to accurately estimate frequencies, especially with rare 
events. 
The duplication may be translated into a truncated protein that lacks the C-
terminal amino acids needed for a proper folding of the protein, nuclear 
localization, and binding to the RAD51 paralogs. Thus, the duplication may 
disturb the formation of the RAD51C complex. Functional studies are required to 
further characterize the duplication at the protein level and the ovarian cancer 
risk association should be validated in larger datasets. 
6.7 PREVALENCE OF RAD51C AND RAD51D
MUTATIONS
While most studies on RAD51C and RAD51D have investigated out-bred 
populations and identified few very rare or unique mutations, the point 
mutations identified in Studies I and II were recurrent in the Finnish population. 
The shared common haplotype in the RAD51C and RAD51D mutation carrier 
families indicates that the identified mutations represent Finnish founder 
mutations. This is typical for the isolated Finnish population, where recurrent 
founder mutations in many disease genes, such as BRCA1, BRCA2, PALB2, and 
CHEK2, account for a majority of all the identified mutations in the genes 166-168. 
The 1% RAD51C and 0.6% RAD51D mutation frequencies observed among 
unselected ovarian cancer patients are higher than the approximately 0.3-0.6% 
overall mutation frequencies observed by Song et al. and Norquist et al. 247, 254. 
The 0.4% frequency of the RAD51C duplication among unselected ovarian cancer 
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patients was similar to the 0.5% frequencies of the c.93delG and c.837+1G>A 
RAD51C mutations individually and together they are observed at a combined 
1.4% frequency among unselected ovarian cancer patients and at a 2.1% 
frequency among patients with personal or family history of ovarian cancer. As 
no other loss-of-function mutations in RAD51D and only a few additional 
singleton mutations in RAD51C are reported in the gnomAD database of among 
over 10 000 Finnish samples 235, it is unlikely that other major mutations in these 
genes exist in the Finnish population. No other reports on RAD51D mutations in 
Finnish breast or ovarian cancer patients have been published in the literature, 
whereas another Finnish study on RAD51C was published soon after Study I. 
Vuorela et al. detected one deleterious RAD51C mutation (c.-13_14del27) among 
147 familial breast cancer patients from Northern Finland and another mutation 
(c.774delT) among 208 unselected ovarian cancer patients from Sweden 237. The 
c.-13_14del27 is not present in gnomAD and likely represents a unique mutation, 
while the Swedish c.774delT mutation is detected only among the non-Finnish 
Europeans. Thus, it is likely that the recurrent mutations identified in this study 
account for the majority of all pathogenic RAD51C and RAD51D mutations in 
Finns, although other very rare or unique susceptibility alleles in these genes may 
also exist in the Finnish population.  
Summary and conclusions 
68 
7 SUMMARY AND CONCLUSIONS
In this thesis study, recurrent founder mutations in the RAD51C and RAD51D 
genes were identified in Finnish breast and ovarian cancer families. Results from 
the extensive screening in breast, ovarian, prostate, and colorectal cancer 
patients suggest that the mutations increase the risk of ovarian cancer. Mutations 
in both genes were significantly more frequent in patients with a personal or 
family history of ovarian cancer than in population controls. The RAD51C 
mutation frequency was also significantly increased among familial and 
unselected ovarian cancer patients. The highest frequency of the RAD51D 
mutation was among breast-ovarian cancer families and it was also enriched in 
unselected ovarian cancer patients, although not reaching statistical significance. 
In contrast, mutations in neither gene were enriched in breast cancer patients, 
suggesting that they do not increase the risk of breast cancer, but rather that 
other breast cancer susceptibility alleles may be segregating in some of the 
mutation carrier families. The absence of the mutations among prostate and 
colorectal cancer patients suggests that RAD51C and RAD51D mutations do not 
predispose to these cancers. The RAD51C ex1-7 duplication identified in the 
gene-panel sequencing also associated with ovarian cancer risk and represented 
a large proportion of all the identified RAD51C mutations. Approximately 2% of 
unselected ovarian cancer patients in Finland are estimated to carry either a 
truncating RAD51C or RAD51D point mutation or the RAD51C duplication. 
Altogether, the gene-panel testing identified pathogenic or potentially 
pathogenic mutations in approximately 20% of the high-risk breast or ovarian 
cancer patients, with two patients carrying two different protein-truncating 
mutations. Notably, more than half of the mutations were observed in genes 
other than BRCA1 or BRCA2. Our results, together with other studies, highlight 
the advantage of comprehensive gene-panel testing, including a CNV detection 
method, as information on different types of mutations in all the relevant genes 
can in this way be obtained simultaneously.  
The role of the RAD51C and RAD51D genes in breast and ovarian cancer 
predisposition have been extensively investigated by others, too. The ovarian 
cancer association for both genes has been confirmed and more precise risk 
estimates have recently been obtained. The results of other studies also indicate 
that RAD51C mutations do not increase the overall risk of breast cancer, although 
their role in the triple-negative subtype remains to be determined. Recent gene-
panel studies, however, suggest that RAD51D mutations may be associated with 
moderately increased risk of breast cancer. In the future, it would be interesting 
to study both genes in specific breast cancer subtypes, such as TNBC, as well as 
in other cancers in large international cohorts. The prognosis and average age at 
disease onset of ovarian cancer patients with RAD51C or RAD51D mutations also 
warrant further research along with other clinical features and tumor 
phenotypes associated with the mutations. 
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The results of this thesis study have clinical value for the diagnostic testing of 
patients and for estimating the cancer risks associated with the RAD51C and 
RAD51D mutations in mutation carrier families. Recurrent founder mutations 
enable a rapid first-phase testing for susceptible carriers, whereas gene panels 
allow comprehensive and cost-effective screening of multiple genes. The RAD51C 
and RAD51D genes are now included in the gene panels used for clinical genetic 
testing of hereditary ovarian cancer as well as hereditary breast and ovarian 
cancer in Finland 286, 287 as well as in many commercially available panels 3, 238, 255.  
Multigene-panel testing is typically offered only for women fulfilling certain 
clinical criteria, such as a positive family history or early-onset disease, but it has 
been suggested that genetic testing should be offered for all women with invasive 
ovarian carcinoma 288, 289. Currently, BRCA1/2 testing is recommended for all 
ovarian cancer patients in some countries, although some countries restrict 
testing to the serous type 288, 290. This strategy may prevent new ovarian cancers 
in the mutation carrier families as mutation-positive healthy relatives can be 
offered preventive measures, and it has also therapeutic implications as BRCA1/2 
mutated ovarian cancers are typically sensitive to platinum treatment and PARP 
inhibitors. In Finland, FINGOG recommends testing all non-mucinous epithelial 
ovarian tumors for somatic BRCA1/2 mutations in order to identify patients 
eligible for olaparib treatment 291. Mutation-positive cases are subsequently 
tested for germline BRCA1/2 mutations to identify inherited predisposition, but 
gene-panel testing is restricted to high-risk patients. The UK National Institute 
for Health and Care Excellence (NICE) guidelines for Familial breast cancer 
recommends BRCA1/2 testing for all patients with ≥10% risk of being a mutation 
carrier, but currently there are no standard guidelines for testing ovarian cancer 
patients or recommendations for gene-panel testing 292. The US National 
Comprehensive Cancer Network (NCCN) guidelines recommend genetic testing 
for all ovarian cancer patients, either in the context of BRCA1/2 testing or gene-
panel testing 293.  
The estimated up-to-10% penetrance of RAD51C and RAD51D mutations is 
likely not enough to result in the clustering of ovarian cancers in families, and 
thus family-history-based screening would miss most mutation carriers. 
Likewise, screening all ovarian cancer patients for RAD51C and RAD51D 
mutations may not substantially reduce ovarian cancer incidence, but it might 
have therapeutic implications as RAD51C and RAD51D deficient cells are also 
sensitive to PARP inhibitors. To prevent future ovarian cancers in the mutation 
carriers, testing of RAD51C or RAD51D mutations in all women in the population 
would perhaps be the most effective 290. In fact, population-based panel testing 
of BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and PALB2 mutations is estimated to 
be more cost-effective than clinical criteria-based panel and BRCA1/2 testing 283, 
but the acceptability and uptake of such testing has not been evaluated. Thus, if 
population-based RAD51C and RAD51D testing is considered, it should be 
performed in the context of gene-panel testing and the psychological effects of 
the testing should be carefully evaluated first. Identified carriers of breast-cancer 
susceptibility alleles may benefit from more careful surveillance, and can opt for 
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preventive measures such as prophylactic bilateral mastectomy. As there are no 
effective pre-symptomatic screening methods for ovarian cancer, it is important 
to identify high-risk women, and preventive measures such as risk-reducing 
salpingo-oophorectomy can be offered to women carrying germline 
susceptibility alleles. Although risk-reducing salpingo-oophorectomy is 
traditionally offered to high-risk women, it may be beneficial also for women 
with an intermediate >4-5% lifetime risk of ovarian cancer and could thus be 
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